CN1262676A - 吡啶衍生物 - Google Patents

吡啶衍生物 Download PDF

Info

Publication number
CN1262676A
CN1262676A CN98807050A CN98807050A CN1262676A CN 1262676 A CN1262676 A CN 1262676A CN 98807050 A CN98807050 A CN 98807050A CN 98807050 A CN98807050 A CN 98807050A CN 1262676 A CN1262676 A CN 1262676A
Authority
CN
China
Prior art keywords
methyl
phenyl
pyridine
pyridin
vinyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN98807050A
Other languages
English (en)
Other versions
CN1203060C (zh
Inventor
H·阿尔格尔
Y·奥伯森
M·比奥拉茨
N·D·科斯夫德
F·加斯帕里尼
R·赫克肯多恩
E·C·约翰逊
R·库恩
M·A·瓦内
G·威里瑟雷比
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Spel Neuroscience Inc
Novartis AG
Original Assignee
Spel Neuroscience Inc
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27128958&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1262676(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Spel Neuroscience Inc, Novartis AG filed Critical Spel Neuroscience Inc
Publication of CN1262676A publication Critical patent/CN1262676A/zh
Application granted granted Critical
Publication of CN1203060C publication Critical patent/CN1203060C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/06—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/06—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
    • C07D213/16—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom containing only one pyridine ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/26—Radicals substituted by halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46—Oxygen atoms
    • C07D213/50—Ketonic radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/52—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/53—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/55—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/57—Nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/30—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/28—Halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

式Ⅰ化合物其中X和R1至R5如说明书中所定义,可用于治疗完全或部分由mGluR5介导的疾病。

Description

吡啶衍生物
本发明涉及2-芳基烯基-，2-杂芳基烯基-，2-芳基炔基-，2-杂芳基炔基-，2-芳基偶氮-和2-杂芳基偶氮吡啶类在调节mGluRs活性及治疗mGluR5介导的疾病中的用途，用于这种治疗中的药物组合物，以及新的2-芳基烯基-，2-杂芳基烯基-，2-芳基炔基-，2-杂芳基炔基-，2-芳基偶氮-和2-杂芳基偶氮吡啶类。
已经发现2-芳基烯基-，2-杂芳基烯基-，2-芳基炔基-，2-杂芳基炔基-，2-芳基偶氮-和2-杂芳基偶氮吡啶类及其可药用盐(此后称为本发明化合物)可用作mGluRs调节剂。多种方式可以证明其对mGluRs的调节作用，特别是结合测定和功能测定，如第二信使测定或细胞内钙浓度变化的测定。例如，在表达hmGluR5a的重组细胞系中测定肌醇磷酸转化数时显示对所选择的本发明化合物的IC50值约为1nM至约50μM。
特别地，本发明化合物具有有价值的药理性质。例如，它们对人体促代谢的(metabotropic)谷氨酸受体(mGluRs)显示显著的和选择性的调节作用，特别是拮抗作用。例如，这种作用可以通过体外对重组人体促代谢的(metabotropic)谷氨酸受体，特别是其PLC-偶联亚型如GluR5用不同方法测定，例如根据L.P.Daggett等人《神经药理学》(Neuropharm.)，第34卷，第871-886页(1995)、P.J.Flor等人《神经化学杂志》(J.Neurochem.)，第67卷，第58-63页(1996)所述方法测定对激动剂诱发细胞内Ca2+浓度升高的抑制作用或者如T.Knoepfel等人《欧洲药理学杂志》(Eur.J.Pharmcol.)，第288卷，第389-392页(1994)、L.P.Daggett等人《神经药理学》(Neuropharm.)，第67卷，第58-63页(1996)(两篇文献在其中引作参考)所述方法测定激动剂诱发肌醇磷酸转化数升高的被抑制程度。人体mGluR亚型的分离和表达被描述在US专利5,521,297中。本发明所选择的化合物在表达hmGluR5a的重组细胞中所测定的抑制使君子氨酸-诱发的肌醇磷酸转化数的IC50值约为1nM至约50μM。
因此本发明涉及本发明化合物在治疗与谷氨酸能(glutamatergic)信号传递异常相关的疾病，以及完全或部分由mGluR5a介导的神经系统疾病中的用途。
与谷氨酸能的信号传递异常相关的疾病是，例如癫痫，脑缺血，特别是急性缺血，眼局部缺血疾病，肌肉痉挛如局部或全身性痉挛，特别是惊厥或疼痛。
完全或部分由mGluR5a介导的神经系统疾病是，例如急性、创伤性和慢性神经系统变性过程，如帕金森疾病，老年痴呆症，阿尔茨海默氏病，亨廷顿氏舞蹈病、肌萎缩性脊髓侧索硬化和脑脊髓多发性硬化，神经病学疾病如神经分裂症和焦虑症，抑郁症和疼痛。
本发明还涉及本发明化合物在治疗与谷氨酸能信号传递异常相关的疾病，以及完全或部分由组I mGluRs介导的神经系统疾病中的用途。
本发明进一步涉及本发明化合物在制备治疗与谷氨酸能信号传递异常相关的疾病及完全或部分由组I mGluRs介导的神经系统疾病的药物组合物中的用途。
本发明另一方面涉及治疗完全或部分由组I mGluRs(优选mGluR5)介导的疾病的方法，该方法包括以治疗有效量的本发明化合物对需要治疗的温血生物体给药。
本发明再一方面还涉及新的2-芳基烯基-，2-杂芳基烯基-，2-芳基炔基-，2-杂芳基炔基-，2-芳基偶氮-和2-杂芳基偶氮吡啶类及其盐，以及它们的制备方法。
本发明还涉及药物组合物，包含作为药物活性成分的本发明的新的2-芳基烯基-，2-杂芳基烯基-，2-芳基炔基-，2-杂芳基炔基-，2-芳基偶氮-和2-杂芳基偶氮吡啶或其可药用盐及常规药物赋形剂。
例如本发明化合物是式I所示的化合物，常规光亲和性配体(photoaffinity ligands)和常规放射性标记物，包括其N-氧化物及其可药用盐
Figure A9880705000271
其中
R1代表氢，低级烷基，羟基-低级烷基，低级烷基氨基，哌啶子基，羧基，酯化羧基，酰胺化羧基，未取代或被低级烷基-、低级烷氧基-，卤素-和/或三氟甲基-取代的N-低级烷基-N-苯基氨基甲酰基，低级烷氧基，卤代-低级烷基或卤代-低级烷氧基，
R2代表氢，低级烷基，羧基，酯化羧基，酰胺化羧基，羟基-低级烷基，羟基，低级烷氧基或低级链烷酰氧基，4-(4-氟-苯甲酰基)-哌啶-1-基-羧基，4-叔丁氧羰基-哌嗪-1-基-羧基，4-(4-叠氮基-2-羟基苯甲酰基)-哌嗪-1-基-羧基或4-(4-叠氮基-2-羟基-3-碘-苯甲酰基)-哌嗪-1-基-羧基，
R3代表氢，低级烷基，羧基，低级烷氧基-羰基，低级烷基-氨基甲酰基，羟基-低级烷基，二-低级烷基-氨基甲基，吗啉代羰基或4-(4-氟-苯甲酰基)-哌嗪-1-基-羧基，
R4代表氢，低级烷基，羟基，羟基-低级烷基，氨基-低级烷基，低级烷氨基-低级烷基，二-低级烷基氨基-低级烷基，未取代或被羟基-取代的低级亚烷基氨基-低级烷基，低级烷氧基，低级链烷酰氧基，氨基-低级烷氧基，低级烷氨基-低级烷氧基，二-低级烷基氨基-低级烷氧基，苯二酰亚氨基-低级烷氧基，未取代或者被羟基-或2-氧代-咪唑烷-1-基-取代的低级亚烷基氨基-低级烷氧基，羧基，酯化或酰胺化羧基，羧基-低级烷氧基或酯化羧基-低级烷氧基，
X代表经由不饱和碳原子连接的可任选被卤素-取代的低级亚烯基或亚炔基，或偶氮(-N＝N-)基团，及
R5代表未取代或被下列一个或多个取代基取代的芳基或杂芳基：低级烷基，卤素，卤代-低级烷基，卤代-低级烷氧基，低级烯基，低级炔基，未取代或被低级烷基-、低级烷氧基、卤素-和/或三氟甲基-取代的苯基，未取代或被低级烷基-、低级烷氧基-、卤素-和/或三氟甲基-取代的苯基-低级炔基，羟基，羟基-低级烷基，低级链烷酰氧基-低级烷基，低级烷氧基，低级烯氧基，低级亚烷二氧基，低级链烷酰氧基，氨基-，低级烷基氨基-，低级链烷酰氨基-或N-低级烷基-N-低级链烷酰氨基-低级烷氧基，未取代或被低级-烷基-、低级烷氧基-、卤素-和/或三氟甲基-取代的苯氧基，未取代或被低级烷基-、低级烷氧基-、卤素-和/或三氟甲基-取代的苯基-低级烷氧基，酰基，羧基，酯化的羧基，酰胺化的羧基，氰基，羧基-低级烷氨基，酯化羧基-低级烷氨基，酰胺化羧基-低级烷氨基，膦酰基-低级烷氨基，酯化膦酰基-低级烷氨基，硝基，氨基，低级烷基氨基，二-低级烷基氨基，酰氨基，N-酰基-N-低级烷基氨基，苯基氨基，苯基-低级烷基氨基，环烷基-低级烷基氨基或杂芳基-低级烷基氨基，其中每个可以是未取代的或被低级烷基-、低级烷氧基-、卤素和/或三氟甲基取代的。
具有碱性基团的式I化合物可以形成酸加成盐，而具有酸性基团的式I化合物可以与碱形成盐。具有碱性基团并且其中至少具有一个酸性基团的式I化合物还可以形成内盐。
本发明还包括全盐(total salt)和部分盐(partial salt)，即每摩尔式I的酸与1、2或3，优选2当量的碱所形成的盐，或每摩尔式I的碱与1、2或3当量，优选1当量的酸所形成的盐。
为了分离或纯化的目的，亦可使用不可药用盐。治疗上仅使用可药用、无毒盐，因此它们是优选的。
在本说明书中卤素指氟、氯、溴或碘。
当X代表亚烯基时，反式构型是优选的。
优选的式I化合物是其中取代基为如下所定义的化合物
X代表经由附近不饱和碳原子键连的可任选被卤素-取代的(C2-4)亚烯基或亚炔基，
R1是氢，(C1-4)烷基，(C1-4)烷氧基，羟基(C1-4)烷基，氰基，乙炔基，羧基，(C1-4)烷氧羰基，二(C1-4)烷基氨基，(C1-6)烷氨基羰基，三氟甲基苯基氨基羰基，
R2是氢，羟基，(C1-4)烷基，羟基(C1-4)烷基，(C1-4)烷氧基，羧基，(C2-5)链烷酰氧基，(C1-4)烷氧羰基，二(C1-4)烷基氨基(C1-4)链烷酰基，二(C1-4)烷基氨基甲基，4-(4-氟-苯甲酰基)-哌啶-1-基-羧基，4-叔丁氧羰基-哌嗪-1-基-羧基，4-(4-叠氮基-2-羟基苯甲酰基)-哌嗪-1-基-羧基或4-(4-叠氮基-2-羟基-3-碘-苯甲酰基)-哌嗪-1-基-羧基，
R3是氢，(C1-4)烷基，羧基，(C1-4)烷氧羰基，(C1-4)烷基氨基甲酰基，羟基(C1-4)烷基，二(C1-4)烷基氨基甲基，吗啉代羰基或4-(4-氟-苯甲酰基)-哌啶-1-基-羧基，
R4是氢，羟基，(C1-4)烷氧基，羧基，(C2-5)链烷酰氧基，(C1-4)烷氧羰基，氨基(C1-4)烷氧基，二(C1-4)烷基氨基(C1-4)烷氧基，二(C1-4)烷基氨基(C1-4)烷基，羧基(C1-4)烷基羰基，(C1-4)烷氧羰基(C1-4)烷氧基，羟基(C1-4)烷基，二(C1-4)烷基氨基(C1-4)烷氧基，间-羟基-对-叠氮基苯基羰基氨基(C1-4)烷氧基，以及
R5是下列基团其中
Ra和Rb独立地是氢，羟基，卤素，硝基，氰基，羧基，(C1-4)烷基，(C1-4)烷氧基，羟基(C1-4)烷基，(C1-4)烷氧羰基，(C2-7)链烷酰基，(C2-5)链烷酰氧基，(C2-5)链烷酰氧基(C1-4)烷基，三氟甲基，三氟甲氧基，三甲基甲硅烷基乙炔基，(C2-5)炔基，氨基，叠氮基，氨基(C1-4)烷氧基，(C2-5)链烷酰氨基(C1-4)烷氧基，(C1-4)烷基氨基(C1-4)烷氧基，二(C1-4)烷基氨基(C1-4)烷氧基，(C1-4)烷基氨基，二(C1-4)烷基氨基，单卤代苄基氨基，噻吩基甲基氨基，噻吩基羰基氨基，三氟甲基苯基氨基羰基，四唑基，(C2-5)链烷酰氨基，苄基羰基氨基，(C1-4)烷基氨基羰基氨基，(C1-4)烷氧羰基-氨基羰基氨基或(C1-4)烷基磺酰基，
Rc是氢，氟，氯，溴，羟基，(C1-4)烷基，(C2-5)链烷酰氧基，(C1-4)烷氧基或氰基，以及
Rd是氢，卤素或(C1-4)烷基。
更优选的式I化合物是其中X如上定义并且其它基团如下定义的化合物
R1是氢，(C1-4)烷基，(C1-4)烷氧基，氰基，乙炔基或二(C1-4)烷基氨基，
R2是氢，羟基，羧基，(C1-4)烷氧羰基，二(C1-4)烷基氨基甲基，4-(4-氟-苯甲酰基)-哌啶-1-基-羧基，4-叔丁氧羰基-哌嗪-1-基-羧基，4-(4-叠氮基-2-羟基苯甲酰基)-哌嗪-1-基-羧基或4-(4-叠氮基-2-羟基-3-碘-苯甲酰基)-哌嗪-1-基-羧基，
R3如上定义，
R4是氢，羟基，羧基，(C2-5)链烷酰氧基，(C1-4)烷氧羰基，氨基(C1-4)烷氧基，二(C1-4)烷基氨基(C1-4)烷氧基，二(C1-4)烷基氨基(C1-4)烷基或羟基(C1-4)烷基，以及
R5是下列基团
其中
Ra和Rb独立地是氢，卤素，硝基，氰基，(C1-4)烷基，(C1-4)烷氧基，三氟甲基，三氟甲氧基或(C2-5)炔基，以及
Rc和Rd如上定义。
本发明化合物包括，例如在后面实施例中描述的化合物。
本发明化合物在治疗上述疾病中的用途可以在标准试验(包括下文所述的那些)中得到证实。
以剂量约10至100mg/kg腹膜内(i.p.)或经口(p.o.)经口，预处理时间为15分钟至8小时，本发明化合物在电休克诱发惊厥模型中显示出抗惊厥活性[参考E.A.Swinyard，J.Pharm.Assoc.Scient.Ed.38，201(1949)和J.Pharmacol.Exptl.Therap.106，319(1952)]。
以剂量约4至约40mg/kg经口(p.o.)给药，本发明化合物显示逆转弗罗因德氏完全佐剂(FCA)诱发的痛觉过敏[参考J.Donnerer等人，Neuroscience 49，693-698(1992)和C.J.Woolf，Neuroscience62，327-331(1994)]。
对于上述所有说明，当然适当的剂量可以依据，例如使用的化合物、宿主、给药方式及要治疗的症状的性质和严重程度变化。但是，一般显示，在动物中获得满意结果的日剂量约为0.5至约100mg/kg(动物体重)。在较大的动物，例如人中，本发明化合物日剂量范围是从约5至1500mg、优选约10至约1000mg，通常以分开剂量最多4次或缓释的形式给药。
上述优选化合物包括(3-{2-[2-反式-(3，5-二氯苯基)-乙烯基]-6-甲基-吡啶-3-基氧}-丙基)-二甲基胺(A)、2-甲基-6-苯乙烯基-吡啶(B)、2-(3-氟-苯基乙炔基)-6-甲基-吡啶(C)和2-(4-乙氧基-3-三氟甲基-苯基乙炔基)-6-甲基-吡啶(D)。例如，已经测定了在上述电休克诱发的惊厥模型中，分别以ED50s为30和35mg/kg腹膜内给药(预处理时间分别为4小时和15分钟)，化合物A和B显示抗惊厥活性；在上述FCA诱发的痛觉过敏模型中，分别以ED50s为4.2和19mg/kg经口给药(后处理时间3小时)，化合物C和D显示痛觉过敏逆转。
如上所述，本发明化合物包括新的2-芳基烯基-，2-杂芳基烯基-，2-芳基炔基-，2-杂芳基炔基-，2-芳基偶氮-和2-杂芳基偶氮吡啶类及其盐，下文称为“本发明化合物”。
本发明化合物包括如上定义的式I化合物及其盐，其中X和R1至R5如上定义，条件是当R3是氢时，a)在其中R1，R2和R4是氢的式I化合物中，当X代表亚乙烯基时，R5不是苯基，一卤代苯基，2，4-和3，4-二氯苯基，3-和4-三氟甲基苯基，甲基苯基，3，4-和2，5-二甲基苯基，4-异丙基苯基，3，5-二-叔丁基苯基，甲氧基苯基，3，4-二甲氧基苯基，2，4，5-和3，4，5-三甲氧基苯基，羟基苯基，3，5-二羟基苯基，4-羟基-3，5-二甲基-苯基，3-羟基-4-甲氧基-和4-羟基-3-甲氧基-苯基，4-羟基-(3-甲基-5-叔丁基-，2-和4-乙酰氨基)苯基，3，5-二异丙基-和3，5-二-叔丁基)苯基，4-羧基-和4-乙氧羰基)苯基，4-氰基苯基，3-甲氧羰基苯基，3-羧基-5-甲氧基-苯基，2-吡啶基，5-氯-2-吡啶基和6-甲基-2-吡啶基，或者当X代表与R5在2位上连接的1，2-亚丙烯基时，R5不是苯基，4-甲基苯基，4-甲氧基苯基，4-溴苯基和2-和4-氯苯基，或者当X代表与R5在1位上连接的1，2-亚丙烯基时，R5不是苯基，2-和4-氯苯基和3-甲氧基苯基，或者当X代表与R5在2位上连接的2，3-亚丁-2-烯基或1，2-亚丁-1-烯基时，R5不是4-甲氧基苯基，或者当X代表与R5在3位上连接的2，3-亚戊-2-烯基时，R5不是4-甲氧基苯基和4-异丙基苯基，或者当X代表3，4-亚己-3-烯基时，R5不是苯基，4-甲基苯基，甲氧基苯基和4-羟基苯基；
b)在其中R1是甲基及R2和R4是氢的式I化合物中，当X代表亚乙烯基时，R5不是苯基，3-甲基苯基，2-甲氧基苯基，2-氯苯基，4-氰基苯基，2-吡啶基和6-甲基-2-吡啶基；
c)在其中R1和R2是氢及R4是羧基的式I化合物中，当X是亚乙烯基时，R5不是苯基，3-甲基苯基，4-甲氧基苯基和4-溴苯基；
d)在其中R1和R2是氢及R4是甲基的式I化合物中，，当X是亚乙烯基时。R5不是苯基，3-甲氧基-，4-甲氧基-和3，4-二甲氧基苯基，2-氯-和2，4-二氯苯基和6-甲基-吡啶-2-基或当X是与R5在2位上连接的1，2-亚丙-1-烯基时，R5不是苯基；
e)在其中R1和R2是氢及R4是2-二甲氨基乙氧羰基或3-二甲氨基丙氧羰基的式I化合物中，当X代表亚乙烯基时，R5不是4-甲氧基苯基；
f)在其中R1和R2是氢及R4是2-二甲氧基乙氧基的式I化合物中，当X代表亚乙烯基时，R5不是苯基，4-甲基苯基和4-甲氧羰基苯基；
g)当R1和R2是氢及R4是羟基或乙氧羰基，或当R1和R2是氢及R4是羟基，或当R1是甲基，R2是氢和R4是甲氧基，或R1是丁-1-烯基，R2是氢和R4是氢，或R1是氢及R4是2-二甲氧基乙氧基时，及每一种情况下X均为亚乙烯基时，R5不是苯基，
以及条件是：当R3是氢及X是亚乙炔基时
a’)当R1，R2和R4是氢时，R5不是苯基，2-和4-硝基苯基，4-氨基苯基，4-氯苯基，4-甲基苯基，4-甲氧基苯基，4-乙氧羰基苯基，5-甲酰基-2-甲氧基-苯基，5-羧基-2-甲氧基-苯基和吡啶基；
b’)在其中R2和R4是氢的式I化合物中，当R1是甲基时，R5不是苯基，3-甲基苯基，6-甲基吡啶-2-基和2-甲氧基苯基，当R1代表己氧基时，R5不是6-溴吡啶-2-基；
c’)在其中R2和R4是氢的式I化合物中，当R2是甲基时，R5不是苯基，4-氨基苯基和4-丙基苯基；当R2是乙基时，R5不是苯基，4-氰基苯基和4-戊基苯基；当R2是丁基时，R5不是3-氰基-4-乙氧基-苯基和3-溴-4-甲氧基-苯基；当R2是戊基时，R5不是4-甲氧基苯基和4-丁氧基苯基；当R2是羧基时，R5不是4-叔丁基苯基，3-叔丁基-4-羟基-苯基，4-叔丁基-3-羟基-苯基和4-己氧基苯基；当R2是甲氧羰基或甲基氨基甲酰基时，R5不是苯基；当R2是乙氧羰基时，R4不是3-叔丁基苯基，3-叔丁基-4-羟基-苯基和4-(4-甲基戊基)苯基；当R2是2-甲基丁氧羰基时，R5不是4-戊氧苯基；
d’)在其中R1和R2是氢的式I化合物中，当R4是羟基，甲基，乙基，羧基，甲氧羰基或氨基甲酰基时，R5不是苯基。
优选的本发明化合物是如上定义的本发明化合物。
本发明化合物可以用类似已知的式I化合物的合成方法制备。
例如，本发明式I化合物可以用下述方法制备，该方法包括
a)使式II化合物
与式Y2-R5(III)反应，其中Y1和Y2之一代表低级链烷酰基、另一个代表低级烷基或三芳基正膦亚基甲基，或Y1和Y2之一代表活性酯化羟基、另一个代表基团Y3-X-，其中Y3是氢或金属的基团，及R1，R2，R3，R4和R5如前定义，功能基R1，R2，R3和R4以及R5的功能取代基可以暂时被保护，或者
b)从式IV化合物上消除H-Y4
Figure A9880705000342
其中Y4代表离去基团(electrofugal group)及R1，R2，R3，R4，X和R5如上定义，功能基R1，R2，R3和R4以及R5的功能取代基可以暂时被保护，除去任何暂时保护基，并且如果需要，将上述方法获得的式I化合物转化为不同的式I化合物，拆分可能获得的异构体混合物为单一异构体和/或将上述方法可获得的具有至少一种盐-形成基团的式I化合物转化为盐，或者将上述方法可获得的盐转化为相应的游离化合物或不同的盐。
低级链烷酰基Y2或更优选Y1基团是，例如C1-C3链烷酰基，如甲酰基，乙酰基或丙酰基，特别是甲酰基。低级烷基Y1或更优选Y2是，例如C1-C3烷基，如甲基，乙基或丙基，特别是甲基。三芳基正膦亚基甲基Y2或更优选Y1是，例如三苯基正膦亚基甲基。
当Y1和Y2之一代表活性酯化羟基，另一个代表基团Y3-X-(其中Y3是氢)时，优选根据Heck偶合方法进行所述的缩合，例如，在铜或铜催化剂或贵金属/膦催化剂的存在下，如在三芳基膦存在下的钯或Pd(1I)盐，例如三苯膦和乙酸钯，或在双-三苯膦-二氯化钯的存在下，优选在三-低级烷基胺，例如三甲胺存在下进行，在Cu1-I存在下，在极性有机溶剂如N，N-二-低级烷基链烷酰胺，例如二甲基甲酰胺，二-低级烷基亚砜，例如二甲亚砜，或二噁烷中，在温度约15℃至约120℃，优选在沸点温度下进行比较有利。
Y1和Y2之一代表活性酯化羟基、另一个代表基团Y3-X-(其中Y3是金属基团时，如卤素-镁基团，反应优选根据格利雅(Grignard)方法进行，其中金属中间体优选原位形成。
当Y1和Y2代表低级链烷酰基、另一个代表低级烷基时，式II和III化合物的分子间缩合优选根据Shaw和Wagstaff方法或其许多变体之一进行。
当Y1和Y2代表低级链烷酰基、另一个代表三芳基正膦亚基甲基时，该缩合优选根据熟知的构建Wittig烯的方法进行，优选从相应的氯化三芳基鏻原位形成正膦亚基成分，例如通过后者与金属碱，如碱金属氢化物，如氢化钠，或与金属-有机碱，如低级烷基金属化合物，如丁基锂，或与碱金属醇盐，例如叔丁醇钾，优选在惰性有机溶剂，如芳烃或芳基脂肪烃，例如苯或甲苯中，在约-10℃至约39℃，优选首先在0℃至10℃、然后在室温下反应。
离去基团Y4是，例如酯化羟基，如用有机酸酯化的羟基，例如低级链烷酰氧基或用无机酸酯化的羟基，例如，卤素基团，或叔氨基，如三-低级烷基氨基，例如，三甲基氨基，或低级-亚烷基氨基，低级氮杂亚烷基氨基，低级-氧杂亚烷基氨基或低级硫杂亚烷基氨基，如吡咯烷-1-基，哌啶子基，吗啉代或硫代吗啉代，或相应的季铵基团。
通过保护基对功能基进行保护、保护基本身和除去保护基的反应例如描述在标准方法中。
可以用常规方式从相应的式IV化合物中除去H-Y4。因此，利用共沸蒸馏可以除去水或低级链烷酸，例如，在甲苯中，在弱酸性条件下进行比较有利。在碱性条件下，例如与碱金属醇盐反应可以除去卤化氢，优选在相应的低级烷醇作为溶剂或共溶剂下进行，或通过在叔胺，如三-低级烷基胺存在下加热。
上述反应的起始原料一般是已知的。新的起始原料可以用类似制备已知起始原料的方法获得。
可用常规方式将根据上述方法获得的式I化合物转化为不同的式I化合物，例如游离羧基可被酯化或酰胺化，酯化或酰胺化的羧基可被转化为游离羧基，酯化的羧基可以被转化为未取代或取代的氨基甲酰基，游离氨基可被酰化或烷基化，而游离羟基可被酰化。
同样，用常规方法，如同有机过氧酸反应可将式I化合物氧化，得到相应的吡啶-N-氧化物衍生物。
用本身已知的方法，例如通过用碱或酸处理也可将式I化合物的盐转化为游离化合物。
用本身已知的方法可将所得盐转化为不同的盐。
包括其盐的式I化合物也可以水合物形式获得，或者可以包含用于结晶的溶剂。
由于游离形式的新化合物及其盐形式的紧密关系，上文和下文中有关任何游离化合物及其盐应被理解为包括游离化合物以及相应的盐。
在式I化合物中，每个手性中心的构型可被选择性逆转。例如，携带亲核取代基(如氨基或羟基)的不对称碳原子构型在任选将键联的亲核取代基转化为适当的离去基团并且与引入原来取代基的试剂反应后可通过二级亲核取代而被逆转，或者具有羟基的碳原子构型可以通过用类似欧洲专利申请EP-A-0236734的方法进行氧化和还原而被逆转。
本发明还涉及含有式I化合物的药物组合物。
本发明的可药用化合物例如可用于制备药物组合物，包括有效量的活性组分与大量无机或有机固体或液体、可药用载体的组合。
本发明的药物组合物是用于肠内，如鼻内，直肠或口服，或非肠道，如肌内或静脉给药至温血动物(人和动物)的组合物，这种组合物包括有效剂量的药物活性成分或还包括大量的可药用载体。活性成分的剂量取决于温血动物的种类、体重、年龄和个体症状，个体药物动力学数据，欲治疗的疾病和给药方式。
药物组合物包括约1％至约95％，优选约20％至约90％的活性成分。本发明药物组合物可以是，例如单位剂量形式，如安瓿，小瓶，栓剂，糖锭剂，片剂或胶囊等形式。
本发明药物组合物可以用本身已知的方法制备，例如利用常规的溶解、冷冻、混合、造粒或成型方法制备。
温血动物例如约70kg体重人的给药剂量，特别是对于由谷氨酸能信号传递异常导致或与其相关的疾病，有效的剂量是约每人每天3mg至约3g，优选约10mg至约1g，例如约20mg至500mg，优选分成1-4次(例如可以是同样大小的量)剂量给药。通常，儿童接受成人一半的剂量。个体所需的剂量可以，例如通过测定活性成分的血清浓度来监测，并调整至最佳水平。
下列非限定性实施例用于说明本发明；温度以摄氏度给出，压力以毫巴表示。
                         实施例1
3-[2-(6-甲基吡啶-2-基)-乙烯基]-苯基氰
将2，6-二甲基吡啶(4.2ml，36.28mMol)、3-氰基苯甲醛(4.95g，37.74mMol)在乙酸酐(6.85ml)中的溶液加热回流16小时。然后真空蒸去乙酸酐并将剩余物在柱色谱上(硅胶400g)纯化。首先用甲苯(400ml)然后用甲苯/乙酸乙酯9∶5洗脱该色谱柱。合并含有所需化合物的流出液，真空蒸发。将固体剩余物用二氯甲烷/己烷重结晶，分离得到3.18g白色晶体(熔点：91-92℃)。
                         实施例2
2-[2-(6-甲基吡啶-2-基)-乙烯基]-苯基氰
将2，6-二甲基吡啶(5.8ml，50mMol)、2-氰基苯甲醛(6.81g，52mMol)在乙酸酐(9.5ml)中的溶液加热回流16小时。然后真空蒸除乙酸酐并将剩余物在柱色谱上(硅胶400g)纯化。首先用甲苯(400ml)、然后用甲苯/乙酸乙酯9∶5洗脱该柱。合并含有所需化合物的流出液，真空蒸馏。将固体剩余物用二氯甲烷/二异丙醚重结晶，分离得到白色晶体(熔点：113-114℃)。
                         实施例3
2-甲基-6-[2-(吡啶-4-基)-乙烯基]-吡啶
将2，6-二甲基吡啶(5.8ml，50mMol)、吡啶-4-甲醛(4.9ml，52mMol)在乙酸酐(9.5ml)中的溶液加热回流16小时。然后真空蒸除乙酸酐并将剩余物在柱色谱上(硅胶900g)纯化。首先用甲苯/丙酮4∶1(5L)、然后用甲苯/丙酮3∶1(5L)、最后用甲苯/丙酮2∶1(15L)洗脱该柱。合并含有所需化合物的流出液，真空蒸馏。将固体剩余物用二氯甲烷/二异丙醚重结晶，分离得到0.956g白色晶体(熔点：72-73℃)。
                         实施例4
2-甲基-6-[2-(吡啶-3-基)-乙烯基]-吡啶
将2，6-二甲基吡啶(5.8ml，50mMol)、吡啶-3-甲醛(4.9ml，52mMol)在乙酸酐(9.5ml)中的溶液加热回流10小时。然后真空蒸除乙酸酐并将剩余物在柱色谱上(硅胶900g)纯化。首先用甲苯/丙酮9∶1(7L)、然后用甲苯/丙酮4∶1(5L)、最后用甲苯/丙酮2∶1(5L)洗脱该柱。合并含有所需化合物的流出液，真空蒸馏。将固体剩余物用二氯甲烷/二异丙醚重结晶并且分离得到4.28g无色油状物，在6-8℃放置后固化。
                         实施例5
2-[2-(3-溴苯基)乙炔基]-6-甲基-吡啶
将1.2g(2.8mMol)2-[1，2-二溴-2-(3-溴苯基)-乙基]-6-甲基-吡啶溶解在10ml乙醇中。加入0.9g(16.1mMol)氢氧化钾(粉末)，并将所得悬浮液加热回流4小时。然后将该悬浮液冷却至室温，倾入100ml盐水中并用叔丁基甲基醚萃取(30ml×3)。用30ml盐水洗涤合并的有机相，用硫酸钠干燥，过滤并真空蒸馏。得到0.720g无色油状物状标题化合物，放置后结晶；熔点60-61℃。
起始原料可以如下获得：
a)2-[2-(3-溴苯基)-乙烯基]-6-甲基-吡啶
将24ml(200mMol)2，6-二甲基吡啶和25.6ml(207mMol)3-溴苯甲醛在38ml乙酸酐中的溶液加热回流7.5小时。然后真空蒸除乙酸酐，并将剩余物溶解在500ml 4N盐酸中，用200ml己烷萃取(200ml×2)。然后用叔丁基甲基醚萃取水相(300ml×4)。将合并的有机相用饱和NaHCO3水溶液洗涤(300ml×2)，然后用300ml盐水洗涤一次，用硫酸钠干燥并真空蒸馏得到4.2g无色结晶的标题化合物，熔点58-59℃。
b)2-[1，2-二溴-2-(3-溴苯基)-乙基]-6-甲基-吡啶
将1g(3.6mMol)2-(3-溴-苯基乙炔基)-6-甲基-吡啶溶解在5ml四氯化碳中，并将该溶液加热至55-60℃。滴加0.23ml(4.4mMol)溴(Br2)于1ml四氯化碳中的溶液。将该反应混合物保持在55-60℃30分钟，然后冷却至室温。过滤收集所得沉淀并真空干燥。分离得到1.3g黄色晶体的标题化合物，熔点164-166℃。
                         实施例6
3-[2-(6-甲基吡啶-2-基)-乙炔基]-苯基氰
将1g(8.54mMol)2-乙炔基-6-甲基-吡啶(用类似D.E.Ames等人所述方法制备，《合成》(Synthesis)，1981，364-5)、2.3g(12.8mMol)3-溴-苯基氰、0.47g(0.7mMol)双-(三苯膦)-氯化钯(II)、80mg(0.41mMol)碘化亚铜和1.53ml(15mMol)三乙胺于10ml二甲基甲酰胺中的混合物在90℃下搅拌3小时。将该混合物冷却至室温，倾入水中并用二氯甲烷萃取。用硫酸钠干燥有机相，过滤，蒸发至干并用硅胶色谱纯化，用己烷/乙酸乙酯(4∶1)作为洗脱剂。用己烷结晶所得产物，得到0.53g(28.4％)标题化合物，为棕色晶体，熔点120-3℃。
                         实施例7
用类似实施例1(当X是亚烯基)或实施例5(当X是亚炔基)的方法，可以制备下列式I化合物：
式I化合物 熔点(℃)
2-苯乙烯基-吡啶-3-酚 249-252
2-甲基-6-[2-(3-硝基-苯基)-乙烯基]-吡啶 100-101
2-[2-(2-氯-苯基)-乙烯基]-吡啶 无色油状物
2-甲基-6-苯乙烯基-吡啶 40-42
乙酸6-[2-(2-氯-苯基)-乙烯基]-吡啶-3-基酯 75-77
6-[2-(2-氯-苯基)-乙烯基]-吡啶-3-酚 168-171
乙酸2-[2-(2-氯-苯基)-乙烯基]-吡啶-3-基酯 99-102
2-[2-(2-氯-苯基)-乙烯基]-吡啶-3-酚 232-234
6-甲基-2-苯乙烯基-吡啶-3-酚 261分解
乙酸2-[2-(2-氯-苯基)-乙烯基]-6-甲基-吡啶-3-基酯 92-94
2-[2-(2-氯-苯基)-乙烯基]-6-甲基-吡啶-3-酚 232-234
(Z)-6-甲基-2-苯乙烯基-吡啶-3-酚 145-148
2-[2-(2-氯-苯基)-乙烯基]-6-甲基-吡啶 51-52
2-[2-(2-氟-苯基)-乙烯基]-吡啶 69-70
2-[2-(2-硝基-苯基)-乙烯基]-吡啶 97-99
乙酸2-[2-(4-氯-苯基)-乙烯基]-6-甲基-吡啶-3-基酯 102-103
乙酸6-[2-(4-氯-苯基)-乙烯基]-2-甲基-吡啶-3-基酯 130-131
2-[2-(4-氯-苯基)-乙烯基]-6-甲基-吡啶-3-酚 275-278分解
6-[2-(4-氯-苯基)-乙烯基]-2-甲基-吡啶-3-酚 265-270分解
乙酸6-甲基-2-[2-(2-硝基-苯基)-乙烯基]-吡啶-3-基酯 139-140
6-甲基-2-[2-(2-硝基-苯基)-乙烯基]-吡啶-3-酚 190-195分解
乙酸2-甲基-6-[2-(2-硝基-苯基)-乙烯基]-吡啶-3-基酯 99-100
2-甲基-6-[2-(2-硝基-苯基)-乙烯基]-吡啶-3-酚 230-233分解
乙酸2-[2-(3-氯-苯基)-乙烯基]-6-甲基-吡啶-3-基酯 97-99
乙酸6-[2-(3-氯-苯基)-乙烯基]-2-甲基-吡啶-3-基酯 112-114
2-[2-(3-氯-苯基)-乙烯基]-6-甲基-吡啶-3-酚 232-235
6-[2-(3-氯-苯基)-乙烯基]-2-甲基-吡啶-3-酚 230-232
(Z)-(6-苯乙烯基-吡啶-2-基)-甲醇 69-70
(E)-(6-苯乙烯基-吡啶-2-基)-甲醇 58-60
2，2’-(1，2-亚乙烯基)双[6-甲基]-吡啶 108-110
二甲基-[3-(6-甲基-2-苯乙烯基-吡啶-3-基氧基)-丙基]-胺；盐酸盐 136-139
(E)-6-[2-(2-吡啶基)乙烯基]-2-甲基吡啶 56-57
2-甲基-6-苯乙烯基-吡啶1-氧化物 102-103
2-苯乙烯基-吡啶1-氧化物 156-159
(E)-6-甲基-2-(2-吡啶-2-基-乙烯基)-吡啶-3-酚 240-242
(Z)-6-甲基-2-(2-吡啶-2-基-乙烯基)-吡啶-3-酚；盐酸盐 225-228
6-苯乙烯基-吡啶-2-腈 92-93
2-[2-(2，6-二氯-苯基)-乙烯基]-6-甲基-吡啶 淡黄色油状物
3-甲氧基-6-甲基-2-苯乙烯基-吡啶 淡黄色油状物
6-苯乙烯基-吡啶-2-甲酰胺 141-142
2-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯基氰 113-114
3-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯基氰 91-92
4-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯基氰 131-132
6-苯乙烯基-吡啶-2-羧酸；盐酸盐 209-212
6-苯乙烯基-吡啶-2-羧酸甲酯 87-88
乙酸2-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯基酯 无色油状物
2-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯酚 227-229
乙酸2-甲氧基-4-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯基酯 102-103
2-[2-(3-氯-苯基)-乙烯基]-6-甲基-吡啶 59-61
2-[2-(4-氯-苯基)-乙烯基]-6-甲基-吡啶 83-85
2-[2-(2-氯-苯基)-乙烯基]-5-乙基-吡啶 34-35
1-(6-苯乙烯基-吡啶-2-基)-乙酮 67-68
6-[2-(2-氯-苯基)-乙烯基]-2-甲基-烟酸乙酯 80-82
2-[2-(2-氯-苯基)-乙烯基]-6-甲基-烟酸乙酯 70-72
2-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯甲酸；HCl盐 218-219
3-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯甲酸 150-151
4-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯甲酸 206-207
3-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯甲酸甲酯；HCl盐 237-238
4-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯甲酸甲酯 112-113
2-甲氧基-4-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯酚 118-119
{3-[2-(6-甲基-吡啶-2-基)-乙烯基]苯基}-甲醇；HCl盐 230-231
6-苯乙烯基-吡啶-2-甲酸叔丁酰胺 87-88
2-(2-溴-2-苯基-乙烯基)-6-甲基吡啶；HCl盐 150-154
2-甲基-6-苯基乙炔基-吡啶；HCl盐 146-148
6-苯乙烯基-吡啶-2-甲酸己酰胺；HCl盐 118-125
6-[2-(2-氯-苯基)-乙烯基]-2-甲基-烟酸 219-221分解
2-[2-(2-氯-苯基)-乙烯基]-6-甲基-烟酸 168-170
2-[2-(3，5-二氯-苯基)-乙烯基]-6-甲基-吡啶 75-77
2-甲基-6-[2-(3-三氟甲基-苯基)-乙烯基]-吡啶 44-45
(E)-6-[2-(4-吡啶基)乙烯基]-2-甲基吡啶 72-73
N，N-二乙基-3-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯甲酰胺；HCl盐 227-228
N，N-二乙基-4-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯甲酰胺；HCl盐 183-184
(E)-6-[2-(3-吡啶基)乙烯基]-2-甲基吡啶 淡黄色油状物
{2-[2-(2-氯-苯基)-乙烯基]-6-甲基-吡啶-3-基氧基}-乙酸乙酯 无色胶状物
3-[2-(6-甲基-吡啶-2-基)-乙烯基]-N-(3-三氟甲基-苯基)-苯甲酰胺；HCl盐 249-251
4-[2-(6-甲基-吡啶-2-基)-乙烯基]-N-(3-三氟甲基-苯基)-苯甲酰胺；HCl盐 160-161
2-[2-(3-硝基-苯基)-乙烯基]-吡啶 127-128
6-苯乙烯基-吡啶-2-甲酸(3-三氟甲基-苯基)-酰胺 128-129
2-(6-苯乙烯基-吡啶-2-基)-丙-2-醇，HCl盐 171-174
2-甲基-6-(2-噻吩-2-基-乙烯基)-吡啶，HCl盐 208-211
2-[2-(3-氯-苯基)-乙烯基]-吡啶 51-53
2-[2-(3-氰基-苯基)-乙烯基]-吡啶 85-86
2-[2-(3-溴-苯基)-乙烯基]-6-甲基-吡啶 58-59
2-[2-(3-溴-苯基)-2-氟-乙烯基]-6-甲基-吡啶 58-59
2-[2-(3，5-二甲基苯基)-2-氟-乙烯基]-6-甲基-吡啶 70-72
2-[2-(2，3-二甲氧基-苯基)-乙烯基]-6-甲基-吡啶 无色油状物
2-[2-(2，3-二氯-苯基)-乙烯基]-6-甲基-吡啶 67-68
2-[2-(3-氯-苯基)-1-甲基-乙烯基]-吡啶 无色油状物
{2-[2-(2-氯-苯基)-乙烯基]-6-甲基-吡啶-3-基}-甲醇 87-90
2-甲基-6-[2-(3-甲基甲硅烷基乙炔基-苯基)-乙烯基]-吡啶 淡黄色油状物
2-[2-(3，4-二氟-苯基)-乙烯基]-6-甲基-吡啶 61-62
2-[2-(3-乙炔基-苯基)-乙烯基]-6-甲基-吡啶 淡黄色油状物
2-[2-(3，5-二氟-苯基)-乙烯基]-6-甲基-吡啶 淡黄色油状物
2-[2-(3-氟-苯基)-乙烯基]-6-甲基-吡啶 淡黄色油状物
2-[2-(3-甲氧基-苯基)-乙烯基]-6-甲基-吡啶 淡黄色油状物
2-甲基-6-[2-(3-苯氧基-苯基)-乙烯基]-吡啶 淡黄色油状物
2-[2-(3-苄氧基-苯基)-乙烯基]-6-甲基-吡啶 68-69
2-[2-(2，5-二氟-苯基)-乙烯基]-6-甲基-吡啶 44-45
{2-[2-(2-氯-苯基)-乙烯基]-6-甲基-吡啶-3-基氧基}-乙酸 230-233
(3-{2-[2-(3-氯-苯基)-乙烯基]-6-甲基-吡啶-3-基氧基}-丙基)-二甲基胺 203-205
{6-[2-(2-氯-苯基)-乙烯基]-2-甲基-吡啶-3-基}-甲醇 131-133
2-(3-溴-苯基乙炔基)-6-甲基-吡啶 61-63
2-甲基-6-{2-[3-(3-三氟甲基-苯氧基)-苯基]-乙烯基}-吡啶 淡黄色油状物
2-[2-(3，5-二甲氧基-苯基)-乙烯基]-6-甲基-吡啶 43-45
2-[2-(3-氯-苯基)-乙烯基]-3-甲氧基-6-甲基-吡啶 52-53
乙酸4-溴-2-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯基酯 淡黄色油状物
乙酸3-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯基酯 淡黄色油状物
2-[2-(3，4-二氯-苯基)-乙烯基]-6-甲基-吡啶 73-75
4-溴-2-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯酚 246-248
2-[2-(3，5-二氯-苯基)-乙烯基]-6-甲基-吡啶-3-基乙酸酯 156-158
6-[2-(3，5-二氯-苯基)-乙烯基]-2-甲基-吡啶-3-基乙酸酯 159-161
2-[2-(3，5-二氯-苯基)-乙烯基]-吡啶-3-基乙酸酯 154-156
2-甲基-6-(2-萘-1-基-乙烯基)-吡啶 淡黄色油状物
2-[2-(2，3-二氢-苯并[1，4]二氧英-6-基)-乙烯基]-6-甲基-吡啶 99-101
2-甲基-6-(2-萘-2-基-乙烯基)-吡啶 97-99
2-甲基-6-(2-间-甲苯基-乙烯基)-吡啶 淡黄色油状物
2-{2-[3-(3，5-二氯-苯氧基)-苯基]-乙烯基}-6-甲基-吡啶 淡黄色胶状物
2-[2-(3-氯-苯基)-丙烯基]-6-甲基-吡啶 淡黄色油状物
2-[2-(2，3-二氢-苯并呋喃-5-基)-乙烯基]-6-甲基-吡啶 88-90
2-[2-(4-氟-苯基)-乙烯基]-6-甲基-吡啶 50-51
2-甲基-6-(2-邻-甲苯基-乙烯基)-吡啶 淡黄色油状物
2-甲基-6-(2-对-甲苯基-乙烯基)-吡啶 85-86
2-甲基-6-(2-对-甲苯基-丙烯基)-吡啶 淡黄色油状物
3-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯基胺 126-129
(2，3-二甲氧基-7-硝基-喹喔啉-5-基甲基)-{3-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯基}-胺 淡橙色泡沫状
N-{3-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯基}-乙酰胺 147
N-{3-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯基}-2-苯基-乙酰胺 156
2，2-二甲基-N-{3-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯基}-丙酰胺 166-168
噻吩-2-甲酸{3-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯基}-酰胺 197分解
环己烷甲酸{3-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯基}-酰胺 215
1-(4-溴-苯基)-3-{3-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯基}-脲 197分解
2-甲基-6-[2-(4-硝基-苯基)-乙烯基]-吡啶 134-135
4-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯胺 147-148
2-[2-(3，5-二氯-苯基)-乙烯基]-6-甲基-吡啶-3-酚 218-220
6-[2-(3，5-二氯-苯基)-乙烯基]-2-甲基-吡啶-3-酚 286分解
2-[2-(3，5-二氯-苯基)-乙烯基]-吡啶-3-酚 240-242
2-[2-(6-氯-苯并[1，3]二氧戊环-5-基)-乙烯基]-6-甲基-吡啶 131-132
2-[2-(2，3-二氟-苯基)-乙烯基]-6-甲基-吡啶 55-56
2-[2-(3，4-二氯-苯基)-丙烯基]-6-甲基-吡啶 淡黄色油状物
2-[2-(3，5-二-三氟甲基-苯基)-乙烯基]-6-甲基-吡啶 85-86
乙酸2-甲氧基-6-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯基酯 淡黄色油状物
2-甲氧基-6-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯酚 118-120
2-甲基-6-[2-(2，3，6-三氟-苯基)-乙烯基]-吡啶 59-62
2-[2-(4-氟-3-三氟甲基-苯基)-乙烯基]-6-甲基-吡啶 淡黄色油状物
2-甲基-6-(2，3，6-三氟-苯基乙炔基)-吡啶 93-94
乙酸4-氯-2-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯基酯 淡黄色油状物
乙酸2，6-二叔丁基-4-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯基酯 127-128
3-(6-甲基-吡啶-2-基乙炔基)-苯甲酰胺 187-189
乙酸4-溴-2-甲氧基-6-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯基酯 151-153
2-(6-氯-苯并[1，3]二氧戊环-5-基乙炔基)-6-甲基-吡啶 105-106淡棕色晶体
2-[2-(3，5-二氯-苯基)-乙烯基]-3-甲氧基-6-甲基-吡啶 127-129
2-[2-(3，5-二氯-苯基)-乙烯基]-3-甲氧基-吡啶 111-113
5-叠氮基-2-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯酚 143分解
2-[2-(吡啶-3-基)乙炔基]-6-甲基-吡啶 淡黄色晶体60-61
N-{3-[2-(6-甲基-吡啶-2-基)-乙烯基}-苯基}-琥珀酰胺酸 212-213
1-叔丁基-3-{3-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯基}-脲 191-192
5-({3-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯基氨基}-甲基)-7-硝基-1，4-二氢-喹喔啉-2，3-二酮 250分解
四氢-呋喃-2-甲酸{3-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯基}-酰胺 160-161
(1-{3-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯基氨基甲酰基}-2-苯基-乙基)-氨基甲酸叔丁基酯 无色泡沫
({3-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯基氨基甲酰基}-甲基)-氨基甲酸叔丁基酯 无色泡沫
二乙基-{3-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯基}-胺 217分解
乙基-{3-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯基}-胺 225分解
乙基-{3-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯基}-胺 183分解
2-(2-乙氧基-3，6-二氟-苯基乙炔基)-6-甲基-吡啶 淡黄色油状物
2-(3，5-二氟-苯基乙炔基)-6-甲基-吡啶 淡黄色油状物
2-(3-氟-苯基乙炔基)-6-甲基-吡啶 26-28
2-[2-(3，5-二甲基-苯基)-乙烯基]-6-甲基-吡啶 56-57
2-[2-(3，4-二甲氧基-苯基)-乙烯基]-6-甲基-吡啶 55-56
2-(3，4-二氯-苯基乙炔基)-6-甲基-吡啶 73-74
2-(4-乙氧基-3-三氟甲基-苯基乙炔基)-6-甲基-吡啶 61-62
2-(4-氟-苯基乙炔基)-6-甲基-吡啶 98-100
2-甲基-6-邻-甲苯基乙炔基-吡啶 淡黄色油状物
2-(3，4-二氟-苯基乙炔基)-6-甲基-吡啶 65-68
2-甲基-6-[2-(2，3，5-三氟-苯基)-乙烯基]-吡啶 80-82
1-[3-(6-甲基-吡啶-2-基乙炔基)-苯基]-乙酮 76-78
2-甲基-6-(3-三氟甲基-苯基乙炔基)-吡啶 35-37
2-甲基-6-(3-硝基-苯基乙炔基)-吡啶 99.5-102.5
6-[2-(3，5-二氯-苯基)-乙烯基]-3-甲氧基-2-甲基-吡啶 98-100
{2-[2-(2-氯-苯基)-乙烯基]-6-甲基-吡啶-3-基}-吗啉-4-基-甲酮 123-125
(3-{2-[2-(3，5-二氯-苯基)-乙烯基]-6-甲基-吡啶-3-基氧基}-丙基)-二甲基-胺盐酸盐 207-210
N-{4-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯基}-琥珀酰胺酸 210分解
N-{4-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯基}-2-苯基-乙酰胺 236-237分解
({4-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯基氨基甲酰基}-甲基)-氨基甲酸叔丁酯 144-145分解
1-叔丁基-3-{4-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯基}-脲 209分解
{3-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯基}-噻吩-2-基甲基-胺盐酸盐 161-162
环己基甲基-{3-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯基}-胺盐酸盐 178-179分解
{4-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯基}-噻吩-2-基甲基-胺 100
环己基甲基-{4-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯基}-胺 106-107
2-氨基-N-{3-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯基}-3-苯基-丙酰胺 102
2-氨基-N-{3-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯基}-乙酰胺 105
 2-氨基-N-{4-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯基}-乙酰胺 217-219分解
1-[1-({2-[2-(2-氯-苯基)-乙烯基]-6-甲基-吡啶-3-基氧基}-乙酰基)-哌啶-4-基]-咪唑烷-2-酮 非晶形泡沫
1-{4-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯基氨基}-乙基)-膦酸二甲基酯 橙色非晶形固体
2-[2-(2-甲氧基-苯基)-乙烯基]-6-甲基-吡啶 129-130
2-(3-乙氧基-4-氟-苯基乙炔基)-6-甲基-吡啶 82-83
2-(3-氯-苯基乙炔基)-6-甲基-吡啶 57-59
1-(3-吡啶-2-基乙炔基-苯基)-乙酮 48-51
4-氯-2-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯酚 256-260
4-溴-2-甲氧基-6-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯酚 121-123
2-甲基-6-间-甲苯基乙炔基-吡啶 57-58
2-(2，5-二氟-苯基乙炔基)-6-甲基-吡啶 49-50
2-(3，5-二甲基-苯基乙炔基)-6-甲基-吡啶 淡黄色油状物
2-[2-(3，5-二溴-苯基)-乙烯基]-6-甲基-吡啶 68-70
2-甲基-6-[2-(嘧啶-5-基)-乙炔基]-吡啶 110-112
(2-{2-[2-(3-氯-苯基)-乙烯基]-6-甲基-吡啶-3-基氧基}-乙基)-二甲基胺 165-167
乙酸1-{4-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯基}-乙基酯
3-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯酚 250-251
3-(6-甲基-吡啶-2-基乙炔基)-苯基胺 129-130
N-[3-(6-甲基-吡啶-2-基乙炔基)-苯基]-2-苯基-乙酰胺 133-135分解
噻吩-2-甲酸3-[2-(6-甲基-吡啶-2-基乙炔基)-苯基]-酰胺 156-157分解
2-甲基-(6-噻吩-2-基乙炔基)-吡啶 34-36
3-(6-甲基-吡啶-2-基乙炔基)-苯甲酸乙酯 56-58
2-(3，5-二溴-苯基乙炔基)-6-甲基-吡啶 100∶101
{2-[2-(2-氯-苯基)-乙烯基]-6-甲基-吡啶-3-基甲基}-二甲基胺 227-229分解
(3-{6-[2-(3-氯-苯基)-乙烯基]-2-甲基-吡啶-3-基氧基}-丙基)-二甲基胺 184-186
5-叠氮基-4-碘-2-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯酚 红色玻璃状
2，6-二-叔丁基-4-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯酚 126-127
1-{4-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯基}-乙醇 97-99
2-甲基-6-[2-(嘧啶-2-基)-乙炔基]-吡啶 144-145
[3-(6-甲基-吡啶-2-基乙炔基)-苯基]-苯基-甲酮(methanone) 99-100
6-(6-甲基-吡啶-2-基乙炔基)-3，4-二氢-1H-喹啉-2-酮 189-191
2-(3-{2-[2-(3-氯-苯基)-乙烯基]-6-甲基-吡啶-3-基氧基}-丙基)-异吲哚-1，3-二酮 101-103
3-甲氧基-6-甲基-2-间-甲苯基乙炔基-吡啶 棕色油状物
乙酸2-[2-(6-甲基-吡啶-2-基)-乙烯基]-4-硝基-苯基酯 129-131
6-(6-甲基-吡啶-2-基乙炔基)-2，3-二氢茚-1-酮 160-165
2-甲基-6-[2-(吡嗪-2-基)-乙炔基]-吡啶 95-96
N-甲基-N-(3-{4-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯氧基}-丙基)-乙酰胺 62-70
2-[2-(3，5-二-三氟甲基-苯基)-1-乙氧基-乙烯基]-6-甲基-吡啶 淡黄色油状物
乙酸2-苯基乙炔基-吡啶-3-基酯 棕色油状物
乙酸6-甲基-2-间-甲苯乙炔基-吡啶-3-基酯 棕色油状物
乙酸4-[2-(6-甲基-吡啶-2-基)-乙烯基]-2-硝基-苯基酯 91-93
2-[2-(6-甲基-吡啶-2-基)-乙烯基]-4-硝基-苯酚 275分解
二甲基-[3-(2-苯基乙炔基-吡啶-3-基氧基)-丙基]-胺 淡黄色油状物
二甲基-(3-{4-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯氧基}-丙基)-胺 240-243
1-{4-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯基}-乙酮(ethanone) 56-58
2-(3-氟-苯基乙炔基)-喹啉 81-83
乙酸2-甲基-6-苯乙烯基-吡啶-3-基酯 93-96
4-[2-(6-甲基-吡啶-2-基)-乙烯基]-2-硝基-苯酚 141-143
3-乙氧基-4-[2-(6-甲基-吡啶-2-基)-乙烯基]-2-硝基-苯酚 175-178分解
4-(6-甲基-吡啶-2-基乙炔基)-2-硝基-苯酚 184-187分解
乙酸2-[2-(6-甲基-吡啶-2-基)-乙烯基]-6-硝基-苯基酯 105-110分解
二甲基-[3-(6-甲基-2-苯基乙炔基-吡啶-3-基氧基)-丙基]-胺 黄色胶状物
2-叠氮基-4-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯酚 155-157分解
二甲基-[3-(6-甲基-2-间-甲苯基乙炔基-吡啶-3-基氧基)-丙基]-胺 黄色油状物
2-(3-甲磺酰基-苯基乙炔基)-6-甲基-吡啶 108-110分解
3-{2-[2-(3-氯-苯基)-乙烯基]-6-甲基-吡啶-3-基氧基}-丙胺 186-189
4-叠氮基-N-(3-{2-[2-(3-氯-苯基)-乙烯基]-6-甲基-吡啶-3-基氧基}-丙基)-2-羟基-苯甲酰胺 99-102分解
3-[3-(3-二甲氨基-丙氧基)-6-甲基-吡啶-2-基乙炔基]-苯基氰 黄色胶状物
5-(6-甲基-吡啶-2-基乙炔基)-2，3-二氢茚-1-酮 133-134
2-甲基-6-(2，3，5-三氯-苯基乙炔基)-吡啶 112-114
2-[2-(6-甲基-吡啶-3-基)乙炔基]-6-甲基-吡啶 118-119
二甲基-{3-[6-甲基-2-(3-三氟甲基-苯基乙炔基)-吡啶-3-基氧基]-丙基}-胺 黄色胶状物
2-[2-(6-甲基-吡啶-3-基)乙炔基]-3-甲氧基-6-甲基-吡啶盐酸盐 198-199
2-甲基-6-(5，6，7，8-四氢-萘-2-基乙炔基)-吡啶 50-51
3-[2-(3-氯-苯基乙炔基)-6-甲基-吡啶-3-基氧基]-丙胺 151-153
(3-{4-溴-2-甲氧基-6-[2-(6-甲基-吡啶-2-基)-乙烯基]苯氧基}-丙基)-二甲基胺； 211-215
[6-(3-氟-苯基乙炔基)-吡啶-2-基]-二甲基胺 棕色油状物状物
6’-(3-氟-苯基乙炔基)-3，4，5，6-四氢-2H-[1，2]联吡啶 棕色胶状物
{3-[2-(3-氯-苯基乙炔基)-6-甲基-吡啶-3-基氧基]-丙基}-二甲基胺； 158-160
4-叠氮基-N-{3-[2-(3-氯-苯基乙炔基)-6-甲基-吡啶-3-基氧基]-丙基}-2-羟基-苯甲酰胺 161-163分解
1-[3-(6-甲基-吡啶-2-基乙炔基)-苯基]-1H-[1，2，4]三唑-3-羧酸乙酯 105-110分解
1-[3-(6-甲基-2-苯基乙炔基-吡啶-3-基氧基)-丙基]-哌啶-3-醇 108-109
2-乙炔基-6-(3-氟-苯基乙炔基)-吡啶 89-90
3-甲基-6-(6-甲基-吡啶-2-基乙炔基)-3H-苯并噁唑-2-酮 172-174
1-[3-(6-甲基-吡啶-2-基乙炔基)-苯基]-1H-[1，2，4]三唑-3-羧酸二甲基酰胺 154-157
1-[3-(6-甲基-2-苯基乙炔基-吡啶-3-基氧基)-丙基]-哌啶-4-醇 非晶形白色固体
5-(6-甲基-吡啶-2-基乙炔基)-2-硝基-苯酚 150-151分解
5-[2-溴-2-(6-甲基-吡啶-2-基)-乙烯基]-2-硝基-苯酚 158-159
5-[2-(6-甲基-吡啶-2-基)-反式-乙烯基]-2-硝基-苯酚 171-173
5-[2-(6-甲基-吡啶-2-基)-顺式-乙烯基]-2-硝基-苯酚 108-110
4-叠氮基-2-羟基-N-[3-(6-甲基-吡啶-2-基乙炔基)-苯基]-苯甲酰胺 180-182分解
5-(3-二甲氨基-丙氧基)-6-苯基乙炔基-吡啶-2-甲酸乙酯 160-162
6-甲基-2-苯乙烯基-嘧啶-4-酚 221-225
2-乙基-6-(3-氟-苯基乙炔基)-吡啶 棕色油状物
2-(3，5-二氯-苯基乙炔基)-6-甲基-吡啶 74-76
2-甲基-6-(3-三氟甲氧基-苯基乙炔基)-吡啶 ＜30；棕色晶体
2-甲基-6-(3-[1，2，4]三唑-1-基-苯基乙炔基)-吡啶 128-130
4-(6-甲基-吡啶-2-基乙炔基)-邻苯二甲腈 138-140
2-甲基-6-{2-[3-(1H-四唑-5-基)-苯基]-乙烯基}-吡啶；具有甲酸的化合物 234-240
3-[2-(3，5-二氯-苯基乙炔基)-6-甲基-吡啶-3-基氧基]-丙基胺 97-100
{3-[2-(3，5-二氯-苯基乙炔基)-6-甲基-吡啶-3-基氧基]-丙基}-二甲基-胺 171-173
2-(3，5-二甲基-苯基乙炔基)-3-甲氧基-6-甲基-吡啶 淡黄色油状物
2-[2-(3-氟-苯基)-乙烯基]-6-甲基-吡啶-3-酚 251-253分解
6-(3-氟-苯基乙炔基)-2-甲基-烟酸乙酯 84-86
2-叠氮基-5-(6-甲基-吡啶-2-基乙炔基)-苯酚 153-155分解
6-(3，4-二甲氧基-苯基乙炔基)-5-(3-二甲氨基-丙氧基)-吡啶-2-甲酸乙酯 149-152
2-(4-甲氧基-3-三氟甲基-苯基乙炔基)-6-甲基-吡啶 86-87
2-(3-氟-苯基乙炔基)-6-甲氧基-吡啶 棕色油状物
2-(3-氟-苯基乙炔基)-5-甲基-吡啶 74-76
6-(3，5-二氯-苯基乙炔基)-5-(3-二甲氨基-丙氧基)-吡啶-2-甲酸乙酯 195-198
5-(3-二甲氨基-丙氧基)-6-(3，5-二甲基-苯基乙炔基)-吡啶-2-甲酸乙酯 187-190
6-(3-氟-苯基乙炔基)-2-甲基-烟酸 173-175
[6-(3-氟-苯基乙炔基)-2-甲基-吡啶-3-基]-甲醇 116-118
[4-(4-氟-苯甲酰基)-哌啶-1-基]-[6-(3-氟-苯基乙炔基)-2-甲基-吡啶-3-基]-甲酮 138-140
2-(3-氟-苯基乙炔基)-6-甲基-烟酸乙酯 棕色油状物
2-(3-氟-苯基乙炔基)-4，6-二甲基-吡啶 棕色油状物
6-(3-氟-苯基乙炔基)-N-(5-甲氧基-2，3-二氢茚-2-基甲基)-2-甲基-烟酰胺 157-159
{[6-(3-氟-苯基乙炔基)-2-甲基-吡啶-3-羰基]-氨基}-苯基-乙酸甲酯 133-135
2-甲基-6-(5-甲基-噻吩-2-基乙炔基)-吡啶 58-59
2-甲基-6-(2，3，5-三甲基-苯基乙炔基)-吡啶 棕色油状物
3-{2-[2-(3-氟-苯基)-乙烯基]-6-甲基-吡啶-3-基氧基}-丙-1-醇 86-88
[6-(3-氟-苯基乙炔基)-2-甲基-吡啶-3-基甲基]-二甲基-胺 220-222
2，2-二甲基-丙酸3-[2-(3-氟-苯基乙炔基)-6-甲基-吡啶-3-基氧基]-丙基酯 棕色油状物
2-叠氮基-4-碘-5-(6-甲基-吡啶-2-基乙炔基)-苯酚 140分解
6-叠氮基-2，4-二碘-3-(6-甲基-吡啶-2-基乙炔基)-苯酚 162分解
4-叠氮基-2-羟基-5-碘-N-[3-(6-甲基-吡啶-2-基乙炔基)-苯基]-苯甲酰胺 185分解
乙酸3-乙酰氧基甲基-5-(6-甲基-吡啶-2-基乙炔基)-苄基酯 棕色油状物
(苄基-{[2-(3-氟-苯基乙炔基)-6-甲基-吡啶-3-基氧基]-乙酰基}-氨基)-乙酸乙酯 棕色油状物
2-[2-(3-氟-苯基)-乙烯基]-6-甲基-异烟酸乙酯 76-77
3-[2-(3-氟-苯基乙炔基)-6-甲基-吡啶-3-基氧基]-丙-1-醇 72-74
[3-羟甲基-5-(6-甲基-吡啶-2-基乙炔基)-苯基]-甲醇 115-117
(3-{2-[2-(3，5-二甲基-苯基)-乙烯基]-6-甲基-吡啶-3-基氧基}-丙基)-二甲基-胺 淡黄色胶状物
[4-(4-氟-苯甲酰基)-哌啶-1-基]-{6-[2-(3-氟-苯基)-乙烯基]-2-甲基-吡啶-3-基}-甲酮 156-158
2-[2-(3-氟-苯基)-乙烯基]-6-甲基-异烟酸 245-248
{6-[2-(2-氯-苯基)-乙烯基]-2-甲基-吡啶-3-基}-[4-(4-氟-苯甲酰基)-哌啶-1-基]-甲酮 109-112
2-(3-乙炔基-苯基乙炔基)-6-甲基-吡啶 48-49
(3-{2-[2-(2，6-二氯-苯基)-乙烯基]-6-甲基-吡啶-3-基氧基}-丙基)-二甲基-胺盐酸盐 207-210
(3-{2-[2-(2，3-二氯-苯基)-乙烯基]-6-甲基-吡啶-3-基氧基}-丙基)-二甲基-胺盐酸盐 161-169
4-[6-(3-氟-苯基乙炔基)-2-甲基-吡啶-3-羰基]-哌嗪-1-羧酸叔丁酯 97-99
[6-(3-氟-苯基乙炔基)-2-甲基-吡啶-3-基]-哌嗪-1-基甲酮 250-252分解
[4-(4-叠氮基-2-羟基-苯甲酰基)-哌嗪-1-基]-[6-(3-氟-苯基乙炔基)-2-甲基-吡啶-3-基]-甲酮 186-188分解
(3-{2-[2-(2，4-二氯-苯基)-乙烯基]-6-甲基-吡啶-3-基氧基}-丙基)-二甲基-胺盐酸盐 170-176
2-(3-氟-苯基乙炔基)-6-甲基-异烟酸乙酯 89-91
2-(3-氟-苯基乙炔基)-6-甲基-异烟酸叔丁酯 94-96
2-(3-氟-苯基乙炔基)-6-甲基-异烟酸 231分解
[2-(3-氟-苯基乙炔基)-6-甲基-吡啶-4-基]-甲醇 143-146
[4-(4-氟-苯甲酰基)-哌啶-1-基]-[[2-(3-氟-苯基乙炔基)-6-甲基-吡啶-4-基]-甲酮 156-158
3-烯丙氧基-2-[2-(3，5-二氯-苯基)-乙烯基]-6-甲基-吡啶 105-106
[2-(3-氟-苯基乙炔基)-6-甲基-吡啶-4-基]-吗啉-4-基-甲酮 114-116
乙酸3-(6-甲基-吡啶-2-基乙炔基)-苄基酯 棕色油状物
[2-(3-氟-苯基乙炔基)-6-甲基-吡啶-4-基甲基]-二甲基-胺 209-212
(3-{2-[2-(3，5-二氯-苯基)-丙烯基]-6-甲基-吡啶-3-基氧基}-丙基)-二甲基-胺盐酸盐 182-184
2-(3-氟-苯基乙炔基)-3-甲氧基-6-甲基-吡啶 淡黄色油状物
(3-{2-[2-(3，5-二氯-苯基)-乙烯基]-吡啶-3-基氧基}-丙基)-二甲基-胺盐酸盐 171-174
(4-叠氮基-2-羟基-5-碘-苯基)-{4-[6-(3-氟-苯基乙炔基)-2-甲基-吡啶-3-羰基]-哌嗪-1-基}-甲酮 195-200分解
4-叠氮基-N-{3-[2-(3-氯-苯基乙炔基)-6-甲基-吡啶-3-基氧基]-丙基}-2-羟基-5-碘-苯甲酰胺 142-150分解
4-(2-吡啶-2-基-乙烯基)-苯甲酸乙酯 100-102
(3-{2-[2-(4-氯-苯基)-乙烯基]-6-甲基-吡啶-3-基氧基}-丙基)-二甲基-胺盐酸盐 159-171
[3-(6-甲基-吡啶-2-基乙炔基)-苯基]-甲醇 43-45
6-(3-氟-苯基乙炔基)-烟酸叔丁酯 96-98
(3-{2-[2-(3，4-二氯-苯基)-乙烯基]-6-甲基-吡啶-3-基氧基}-丙基)-二甲基-胺盐酸盐 174-177
2-(1-溴-2-苯基-乙烯基)-4-甲基-嘧啶 黄色油
6-(3-氟-苯基乙炔基)-烟酸 223分解
[4-(4-氟-苯甲酰基)-哌啶-1-基]-[6-(3-氟-苯基乙炔基)-吡啶-3-基]-甲酮 136.0-139.0
2-(2-叔丁氧基-3，6-二氟-苯基乙炔基)-6-甲基-吡啶 72.0-74.0
2-甲基-6-[2-(2，4，5-三氟-苯基)-乙烯基]-吡啶 74-76
2-甲基-6-[2-(2，3，4-三氟-苯基)-乙烯基]-吡啶 79-82
3-(6-甲基-吡啶-2-基乙炔基)-苯酚 142-144
2-甲基-6-[2-(3，4，5-三氟-苯基)-乙烯基]-吡啶 74-76
2-(3-甲氧基-苯基乙炔基)-6-甲基-吡啶 55-57
2-甲基-6-(2，3，4-三氟-苯基乙炔基)-吡啶 104-106

Claims (12)

1. 2-芳基烯基-，2-杂芳基烯基-，2-芳基炔基-，2-杂芳基炔基-，2-芳基偶氮-和2-杂芳基偶氮吡啶或其可药用盐在治疗与谷氨酸能信号传递异常相关的疾病及完全或部分由mGluR5介导的神经系统疾病的中的用途。
2. 2-芳基烯基-，2-杂芳基烯基-，2-芳基炔基-，2-杂芳基炔基-，2-芳基偶氮-和2-杂芳基偶氮吡啶或其可药用盐在治疗癫痫，脑缺血，眼局部缺血疾病，肌肉痉挛，惊厥，疼痛，急性、创伤性和慢性神经系统变性过程和神经病学疾病中的用途。
3.式I化合物、其游离形式、光亲和性配体形式、放射性标记物、N-氧化物或其可药用盐在治疗与谷氨酸能信号传递异常相关的疾病及完全或部分由mGluR5介导的神经系统疾病中的用途
其中
R1代表氢，低级烷基，羟基-低级烷基，低级烷基氨基，哌啶子基，羧基，酯化羧基，酰胺化羧基，未取代或被低级烷基-，低级烷氧基-、卤素-和/或三氟甲基-取代的N-低级-烷基-N-苯基氨基甲酰基，低级烷氧基，卤代-低级烷基或卤代-低级烷氧基，
R2代表氢，低级烷基，羧基，酯化羧基，酰胺化羧基，羟基-低级烷基，羟基，低级烷氧基或低级链烷酰氧基，4-(4-氟-苯甲酰基)-哌啶-1-基-羧基，4-叔丁氧羰基-哌嗪-1-基-羧基，4-(4-叠氮基-2-羟基苯甲酰基)-哌嗪-1-基-羧基或4-(4-叠氮基-2-羟基-3-碘-苯甲酰基)-哌啶-1-基-羧基，
R3代表氢，低级烷基，羧基，低级烷氧基-羰基，低级烷基-氨基甲酰基，羟基-低级烷基，二-低级烷基-氨基甲基，吗啉代羰基或4-(4-氟-苯甲酰基)-哌嗪-1-基-羧基，
R4代表氢，低级烷基，羟基，羟基-低级烷基，氨基-低级烷基，低级烷基氨基-低级烷基，二-低级烷基氨基-低级烷基，未取代或被羟基-取代的低级亚烷基氨基-低级烷基，低级烷氧基，低级链烷酰氧基，氨基-低级烷氧基，低级烷基氨基-低级烷氧基，二-低级烷基氨基-低级烷氧基，苯二酰亚氨基-低级烷氧基，未取代或被羟基-或2-氧代-咪唑烷-1-基-取代的低级亚烷基氨基-低级烷氧基，羧基，酯化或酰胺化羧基，羧基-低级烷氧基或酯化羧基-低级-烷氧基，
X代表经由附近不饱和碳原子连接的可任选被卤素-取代的低级亚烯基或亚炔基或偶氮(-N＝N-)基团，及
R5代表未取代或被下列一个或多个取代基取代的芳基或杂芳基：低级烷基，卤素，卤代-低级烷基，卤代-低级烷氧基，低级烯基，低级炔基，未取代或被低级烷基-、低级烷氧基、卤素-和/或三氟甲基-取代的苯基，未取代或被低级烷基-、低级烷氧基-、卤素-和/或三氟甲基-取代的苯基-低级炔基，羟基，羟基-低级烷基，低级链烷酰氧基-低级烷基，低级烷氧基，低级烯氧基，低级亚烷二氧基，低级链烷酰氧基，氨基-，低级烷基氨基-，低级链烷酰氨基-或N-低级烷基-N-低级链烷酰氨基-低级烷氧基，未取代或被低级-烷基-、低级烷氧基-、卤素-和/或三氟甲基-取代的苯氧基，未取代或被低级烷基-、低级烷氧基-，卤素-和/或三氟甲基-取代的苯基-低级烷氧基，酰基，羧基，酯化羧基，酰胺化羧基，氰基，羧基-低级烷基氨基，酯化羧基-低级烷基氨基，酰胺化羧基-低级烷基氨基，膦酰基-低级烷基氨基，酯化膦酰基-低级烷基氨基，硝基，氨基，低级烷基氨基，二-低级烷基氨基，酰氨基，N-酰基-N-低级烷基氨基，苯基氨基，苯基-低级烷基氨基，环烷基-低级烷基氨基或杂芳基-低级烷基氨基，其中每个可以是未取代的或被低级烷基-、低级烷氧基-、卤素和/或三氟甲基取代。
4.根据权利要求3的化合物的用途，治疗与谷氨酸能信号传递异常相关的疾病及完全或部分由mGluR5介导的神经系统疾病。
5.根据权利要求3的化合物的用途，用于制备治疗与谷氨酸能信号传递异常相关的疾病及完全或部分由mGluR5介导的神经系统疾病的药物组合物。
6.式I化合物、其游离形式、光亲和性配体形式、放射性标记物、N-氧化物或其可药用盐
Figure A9880705000041
其中
R1代表氢，低级烷基，羟基-低级烷基，低级烷基氨基，哌啶子基，羧基，酯化羧基，酰胺化羧基，未取代或被低级烷基-、低级烷氧基-、卤代-和/或三氟甲基-取代的N-低级-烷基-N-苯基氨基甲酰基，低级烷氧基，卤代-低级烷基或卤代-低级烷氧基，
R2代表氢，低级烷基，羧基，酯化羧基，酰胺化羧基，羟基-低级烷基，羟基，低级烷氧基或低级链烷酰氧基，4-(4-氟-苯甲酰基)-哌啶-1-基-羧基，4-叔丁氧羰基-哌嗪-1-基-羧基，4-(4-叠氮基-2-羟基苯甲酰基)-哌嗪-1-基-羧基或4-(4-叠氮基-2-羟基-3-碘-苯甲酰基)-哌嗪-1-基-羧基，
R3代表氢，低级烷基，羧基，低级烷氧基-羰基，低级烷基-氨基甲酰基，羟基-低级烷基，二-低级烷基-氨基甲基，吗啉代羰基或4-(4-氟-苯甲酰基)-哌啶-1-基-羧基，
R4代表氢，低级烷基，羟基，羟基-低级烷基，氨基-低级烷基，低级烷基氨基-低级烷基，二-低级烷基氨基-低级烷基，未取代或被羟基-取代的低级亚烷基氨基-低级烷基，低级烷氧基，低级链烷酰氧基，氨基-低级烷氧基，低级烷基氨基-低级烷氧基，二-低级烷基氨基-低级烷氧基，苯二酰亚氨基-低级烷氧基，未取代或被羟基-或2-氧代-咪唑烷-1-基-取代的低级亚烷基氨基-低级烷氧基，羧基，酯化或酰胺化羧基，羧基-低级-烷氧基或酯化羧基-低级-烷氧基，
X代表经由附近不饱和碳原子连接的可任选被卤素-取代的低级亚烯基或亚炔基或偶氮(-N＝N-)基团，及
R5代表未取代或被下列一个或多个取代基取代的芳基或杂芳基：低级烷基，卤素，卤代-低级烷基，卤代-低级烷氧基，低级烯基，低级炔基，未取代或被低级烷基-、低级烷氧基、卤素-和/或三氟甲基-取代的苯基，未取代或被低级烷基-、低级烷氧基-、卤素-和/或三氟甲基-取代的苯基-低级炔基，羟基，羟基-低级烷基，低级链烷酰氧基-低级烷基，低级烷氧基，低级烯氧基，低级亚烷二氧基，低级链烷酰氧基，氨基-，低级烷基氨基-，低级链烷酰氨基-或N-低级烷基-N-低级链烷酰氨基-低级烷氧基，未取代或被低级-烷基-、低级烷氧基-、卤素-和/或三氟甲基-取代的苯氧基，未取代或被低级烷基-、低级烷氧基-、卤素-和/或三氟甲基-取代的苯基-低级烷氧基，酰基，羧基，酯化羧基，酰胺化羧基，氰基，羧基-低级烷基氨基，酯化羧基-低级烷基氨基，酰胺化羧基-低级烷基氨基，膦酰基-低级烷基氨基，酯化膦酰基-低级烷基氨基，硝基，氨基，低级烷基氨基，二-低级烷基氨基，酰氨基，N-酰基-N-低级烷基氨基，苯基氨基，苯基-低级烷基氨基，环烷基-低级烷基氨基或杂芳基-低级烷基氨基，其中每个可以是未取代的或被低级烷基-、低级烷氧基-、卤素和/或三氟甲基取代的，
条件是当R3是氢时，
a)在其中R1，R2和R4是氢的式I化合物中，当X代表亚乙烯基时，R5不是苯基，一卤代苯基，2，4-和3，4-二氯苯基，3-和4-三氟甲基苯基，甲基苯基，3，4-和2，5-二甲基苯基，4-异丙基苯基，3，5-二-叔丁基苯基，甲氧基苯基，3，4-二甲氧基苯基，2，4，5-和3，4，5-三甲氧基苯基，羟基苯基，3，5-二羟基苯基，4-羟基-3，5-二甲基-苯基，3-羟基-4-甲氧基-和4-羟基-3-甲氧基-苯基，4-羟基-(3-甲基-5-叔丁基-，2-和4-乙酰氨基苯基，3，5-二异丙基-和3，5-二-叔丁基)苯基，4-羧基-和4-乙氧羰基苯基，4-氰基苯基，3-甲氧羰基苯基，3-羧基-5-甲氧基-苯基，2-吡啶基，5-氯-2-吡啶基和6-甲基-2-吡啶基；或者当X代表与R5在2位上连接的1，2-亚丙烯基时，R5不是苯基，4-甲基苯基，4-甲氧基苯基，4-溴苯基和2-和4-氯苯基；或者当X代表与R5在1位上连接的1，2-亚丙烯基时，R5不是苯基，2-和4-氯苯基和3-甲氧基苯基；或者当X代表与R5在2位上连接的2，3-亚丁-2-烯基或1，2-亚丁-1-烯基时，R5不是4-甲氧基苯基；或者当X代表与R5在3位上连接的2，3-亚戊-2-烯基时，R5不是4-甲氧基苯基和4-异丙基苯基；或者当X代表3，4-亚己-3-烯基时，R5不是苯基，4-甲基苯基，甲氧基苯基和4-羟基苯基；
b)在其中R1是甲基及R2和R4是氢的式I化合物中，当X代表亚乙烯基时，R5不是苯基，3-甲基苯基，2-甲氧基苯基，2-氯苯基，4-氰基苯基，2-吡啶基和6-甲基-2-吡啶基；
c)在其中R1和R2是氢及R4是羧基的式I化合物中，当X是亚乙烯基时，R5不是苯基，3-甲基苯基，4-甲氧基苯基和4-溴苯基；
d)在其中R1和R2是氢及R4是甲基的式I化合物中，当X是亚乙烯基时，R5不是苯基，3-甲氧基-，4-甲氧基-和3，4-二甲氧基苯基，2-氯-和2，4-二氯苯基和6-甲基-吡啶-2基，或者当X代表与R5在2位上连接的1，2-亚丙-1-烯基时，R5不是苯基；
e)在其中R1和R2是氢及R4是2-二甲氨基乙氧羰基或3-二甲基氨基丙氧羰基的式I化合物中，当X代表亚乙烯基时，R5不是4-甲氧基苯基；
f)在其中R1和R2是氢及R4是2-二甲氧基乙氧基的式I化合物中，当X代表亚乙烯基时，R5不是苯基，4-甲基苯基和4-甲氧羰基苯基；
g)当R1和R2是氢及R4是羟基或乙氧羰基时，或当R1和R2是氢及R4是羟基时，或当R1是甲基，R2是氢和R4是甲氧基时，或R1是丁-1-烯基，R2是氢和R4是氢，或R1是氢及R4是2-二甲氧基乙氧基时，及每一种情况X均为亚乙烯基时，R5不是苯基，
及条件是：当R3是氢及X是亚乙炔基时，
a’)当R1，R2和R4是氢时，R5不是苯基，2-和4-硝基苯基，4-氨基苯基，4-氯苯基，4-甲基苯基，4-甲氧基苯基，4-乙氧羰基苯基，5-甲酰基-2-甲氧基-苯基，5-羧基-2-甲基-苯基和吡啶基；
b’)在其中R2和R4是氢的式I化合物中，当R1是甲基时，R5不是苯基，3-甲基苯基，6-甲基吡啶-2-基和2-甲氧基苯基，当R1代表溴时，R5不是6-溴吡啶-2-基，以及当R1代表己氧基时，R5不是6-己氧基吡啶-2-基；
c’)在其中R2和R4是氢的式I化合物中，当R2是甲基时，R5不是苯基，4-氨基苯基和4-丙基苯基；当R2是乙基时，R5不是苯基，4-氰基苯基和4-戊基苯基；当R2是丁基时，R5不是3-氰基-4-乙氧基-苯基和3-溴-4-甲氧基-苯基；当R2是戊基时，R5不是4-甲氧基苯基和4-丁氧基苯基；当R2是羧基时，R5不是4-叔丁基苯基，3-叔丁基-4-羟基-苯基，4-叔丁基-3-羟基-苯基和4-己氧基苯基；当R2是甲氧羰基或甲基氨基甲酰基时，R5不是苯基；当R2是乙氧羰基时，R4不是3-叔丁基苯基，3-叔丁基-4-羟基-苯基和4-(4-甲基戊基)苯基；当R2是2-甲基丁氧羰基时，R5不是4-戊氧苯基；
d’)在其中R1和R2是氢的式I化合物中，当R4是羟基，甲基，乙基，羧基，甲氧羰基或氨基甲酰基时，R5不是苯基。
7.根据权利要求6的化合物，其中
X代表经由附近不饱和碳原子连接的可任选被卤素-取代的(C2-4)亚烯基或亚炔基，
R1是氢，(C1-4)烷基，(C1-4)烷氧基，羟基(C1-4)烷基，氰基，乙炔基，羧基，(C1-4)烷氧羰基，二(C1-4)烷基氨基，(C1-6)烷基氨基羰基，三氟甲基苯基氨基羰基，
R2是氢，羟基，(C1-4)烷基，羟基(C1-4)烷基，(C1-4)烷氧基，羧基，(C2-5)链烷酰氧基，(C1-4)烷氧羰基，二(C1-4)烷基氨基(C1-4)链烷酰基，二(C1-4)烷基氨基甲基，4-(4-氟-苯甲酰基)-哌啶-1-基-羧基，4-叔丁氧羰基-哌嗪-1-基-羧基，4-(4-叠氮基-2-羟基苯甲酰基)-哌嗪-1-基-羧基或4-(4-叠氮基-2-羟基-3-碘-苯甲酰基)-哌嗪-1-基-羧基，
R3是氢，(C1-4)烷基，羧基，(C1-4)烷氧羰基，(C1-4)烷基氨基甲酰基，羟基(C1-4)烷基，二(C1-4)烷基氨基甲基，吗啉代羰基或4-(4-氟-苯甲酰基)-哌啶-1-基-羧基，
R4是氢，羟基，(C1-4)烷氧基，羧基，(C2-5)链烷酰氧基，(C1-4)烷氧羰基，氨基(C1-4)烷氧基，二(C1-4)烷基氨基(C1-4)烷氧基，二(C1-4)烷基氨基(C1-4)烷基，羧基(C1-4)烷基羰基，(C1-4)烷氧羰基(C1-4)烷氧基，羟基(C1-4)烷基，二(C1-4)烷基氨基(C1-4)烷氧基，间-羟基-对-叠氮基苯基羰基氨基(C1-4)烷氧基，及
R5是下列基团
其中
Ra和Rb独立地是氢，羟基，卤素，硝基，氰基，羧基，(C1-4)烷基，(C1-4)烷氧基，羟基(C1-4)烷基，(C1-4)烷氧羰基，(C2-7)链烷酰基，(C2-5)链烷酰氧基，(C2-5)链烷酰氧基(C1-4)烷基，三氟甲基，三氟甲氧基，三甲基甲硅烷基乙炔基，(C2-5)炔基，氨基，叠氮基，氨基(C1-4)烷氧基，(C2-5)链烷酰氨基(C1-4)烷氧基，(C1-4)烷基氨基(C1-4)烷氧基，二(C1-4)烷基氨基(C1-4)烷氧基，(C1-4)烷基氨基，二(C1-4)烷基氨基，单卤代苄基氨基，噻吩基甲基氨基，噻吩基羰基氨基，三氟甲基苯基氨基羰基，四唑基，(C2-5)链烷酰氨基，苄基羰基氨基，(C1-4)烷基氨基羰基氨基，(C1-4)烷氧羰基-氨基羰基氨基或(C1-4)烷基磺酰基，
Rc是氢，氟，氯，溴，羟基，(C1-4)烷基，(C2-5)链烷酰氧基，(C1-4)烷氧基或氰基，及
Rd是氢，卤素或(C1-4)烷基。
8.根据权利要求6的化合物，其中
R1是氢，(C1-4)烷基，(C1-4)烷氧基，氰基，乙炔基或二(C1-4)烷基氨基，
R2是氢，羟基，羧基，(C1-4)烷氧羰基，二(C1-4)烷基氨基甲基，4-(4-氟-苯甲酰基)-哌啶-1-基-羧基，4-叔丁氧羰基-哌嗪-1-基-羧基，4-(4-叠氮基-2-羟基苯甲酰基)-哌嗪-1-基-羧基或4-(4-叠氮基-2-羟基-3-碘-苯甲酰基)-哌嗪-1-基-羧基，
R3如权利要求7中所定义，
R4是氢，羟基，羧基，(C2-5)链烷酰氧基，(C1-4)烷氧羰基，氨基(C1-4)烷氧基，二(C1-4)烷基氨基(C1-4)烷氧基，二(C1-4)烷基氨基(C1-4)烷基或羟基(C1-4)烷基，及
R5是下列基团
其中
Ra和Rb独立地是氢，卤素，硝基，氰基，(C1-4)烷基，(C1-4)烷氧基，三氟甲基，三氟甲氧基或(C2-5)炔基，以及
Rc和Rd如权利要求7中所定义。
9.根据权利要求6的化合物，选自下列化合物：3-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯基氰2-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯基氰2-甲基-6-[2-(吡啶-4-基)-乙烯基]-吡啶2-甲基-6-[2-(吡啶-3-基)-乙烯基]-吡啶2-[2-(3-溴苯基)乙炔基]-6-甲基-吡啶3-[2-(6-甲基-吡啶-2-基)乙炔基]-苯基氰2-苯乙烯基-吡啶-3-酚2-甲基-6-[2-(3-硝基-苯基)-乙烯基]-吡啶乙酸6-[2-(2-氯-苯基)-乙烯基]-吡啶-3-基酯6-[2-(2-氯-苯基)-乙烯基]-吡啶-3-酚乙酸2-[2-(2-氯-苯基)-乙烯基]-吡啶-3-基酯2-[2-(2-氯-苯基)-乙烯基]-吡啶-3-酚6-甲基-2-苯乙烯基-吡啶-3-酚乙酸2-[2-(2-氯-苯基)-乙烯基]-6-甲基-吡啶-3-基酯2-[2-(2-氯-苯基)-乙烯基]-6-甲基-吡啶-3-酚(顺)-6-甲基-2-苯乙烯基-吡啶-3-酚2-[2-(2-硝基-苯基)-乙烯基]-吡啶乙酸2-[2-(4-氯-苯基)-乙烯基]-6-甲基-吡啶-3-基酯乙酸6-[2-(4-氯-苯基)-乙烯基]-2-甲基-吡啶-3-基酯2-[2-(4-氯-苯基)-乙烯基]-6-甲基-吡啶-3-酚6-[2-(4-氯-苯基)-乙烯基]-2-甲基-吡啶-3-酚乙酸6-甲基-2-[2-(2-硝基-苯基)-乙烯基]-吡啶-3-基酯6-甲基-2-[2-(2-硝基-苯基)-乙烯基]-吡啶-3-酚乙酸2-甲基-6-[2-(2-硝基-苯基)-乙烯基]-吡啶-3-基酯2-甲基-6-[2-(2-硝基-苯基)-乙烯基]-吡啶-3-酚乙酸2-[2-(3-氯-苯基)-乙烯基]-6-甲基-吡啶-3-基酯乙酸6-[2-(3-氯-苯基)-乙烯基]-2-甲基-吡啶-3-基酯2-[2-(3-氯-苯基)-乙烯基]-6-甲基-吡啶-3-酚6-[2-(3-氯-苯基)-乙烯基]-2-甲基-吡啶-3-酚(顺)-(6-苯乙烯基-吡啶-2-基)-甲醇(反)-(6-苯乙烯基-吡啶-2-基)-甲醇二甲基-[3-(6-甲基-2-苯乙烯基-吡啶-3-基氧基)-丙基]-胺2-甲基-6-苯乙烯基-吡啶1-氧化物2-苯乙烯基-吡啶1-氧化物(反)-6-甲基-2-(2-吡啶-2-基-乙烯基)-吡啶-3-酚(顺)-6-甲基-2-(2-吡啶-2-基-乙烯基)-吡啶-3-酚6-苯乙烯基-吡啶-2-腈2-[2-(2，6-二氯-苯基)-乙烯基]-6-甲基-吡啶6-甲氧基-6-甲基-2-苯乙烯基-吡啶6-苯乙烯基-吡啶-2-甲酰胺2-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯基氰6-苯乙烯基-吡啶-2-甲酸6-苯乙烯基-吡啶-2-甲酸甲酯乙酸2-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯基酯2-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯酚乙酸2-甲氧基-4-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯基酯2-[2-(3-氯-苯基)-乙烯基]-6-甲基-吡啶2-[2-(4-氯-苯基)-乙烯基]-6-甲基-吡啶2-[2-(2-氯-苯基)-乙烯基]-5-乙基-吡啶1-(6-苯乙烯基-吡啶-2-基)-乙酮6-[2-(2-氯-苯基)-乙烯基]-2-甲基-烟酸乙酯2-[2-(2-氯-苯基)-乙烯基]-6-甲基-烟酸乙酯2-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯甲酸3-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯甲酸4-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯甲酸3-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯甲酸甲酯4-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯甲酸甲酯2-甲氧基-4-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯酚{3-[2-(6-甲基-吡啶-2-基)-乙烯基]苯基}-甲醇6-苯乙烯基-吡啶-2-甲酸叔丁酰胺2-(2-溴-2-苯基-乙烯基)-6-甲基吡啶6-苯乙烯基-吡啶-2-甲酸己酰胺6-[2-(2-氯-苯基)-乙烯基]-2-甲基-烟酸2-[2-(2-氯-苯基)-乙烯基]-6-甲基-烟酸2-[2-(3，5-二氯-苯基)-乙烯基]-6-甲基-吡啶2-甲基-6-[2-(3-三氟甲基-苯基)-乙烯基]-吡啶(反)-6-[2-(4-吡啶基)乙烯基]-2-甲基吡啶N，N-二乙基-3-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯甲酰胺N，N-二乙基-4-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯甲酰胺(反)-6-[2-(3-吡啶基)乙烯基]-2-甲基吡啶{2-[2-(2-氯-苯基)-乙烯基]-6-甲基-吡啶-3-基氧基}-乙酸乙酯3-[2-(6-甲基-吡啶-2-基)-乙烯基]-N-(3-三氟甲基-苯基)-苯甲酰胺4-[2-(6-甲基-吡啶-2-基)-乙烯基]-N-(3-三氟甲基-苯基)-苯甲酰胺2-[2-(3-硝基-苯基)-乙烯基]-吡啶6-苯乙烯基-吡啶-2-甲酸(3-三氟甲基-苯基)-酰胺2-(6-苯乙烯基-吡啶-2-基)-丙-2-醇2-甲基-6-(2-噻吩-2-基-乙烯基)-吡啶2-[2-(3-氰基-苯基)-乙烯基]-吡啶2-[2-(3-溴-苯基)-乙烯基]-6-甲基-吡啶2-[2-(3-溴-苯基)-2-氟-乙烯基]-6-甲基-吡啶2-[2-(3，5-二甲基苯基)-2-氟-乙烯基]-6-甲基-吡啶2-[2-(2，3-二甲氧基-苯基)-乙烯基]-6-甲基-吡啶2-[2-(2，3-二氯-苯基)-乙烯基]-6-甲基-吡啶2-[2-(3-氯-苯基)-1-甲基-乙烯基]-吡啶{2-[2-(2-氯-苯基)-乙烯基]-6-甲基-吡啶-3-基}-甲醇2-甲基-6-[2-(3-三甲基甲硅烷基乙炔基-苯基)-乙烯基]-吡啶2-[2-(3，4-二氟-苯基)-乙烯基]-6-甲基-吡啶2-[2-(3-乙炔基-苯基)-乙烯基]-6-甲基-吡啶2-[2-(3，5-二氟-苯基)-乙烯基]-6-甲基-吡啶2-[2-(3-氟-苯基)-乙烯基]-6-甲基-吡啶2-[2-(3-甲氧基-苯基)-乙烯基]-吡啶2-甲基-6-[2-(3-苯氧基-苯基)-乙烯基]-吡啶2-[2-(3-苄氧基-苯基)-乙烯基]-6-甲基-吡啶2-[2-(2，5-二氟-苯基)-乙烯基]-6-甲基-吡啶{2-[2-(2-氯-苯基)-乙烯基]-6-甲基-吡啶-3-基氧基}-乙酸(3-{2-[2-(3-氯-苯基)-乙烯基]-6-甲基-吡啶-3-基氧基}-丙基)-二甲胺{6-[2-(2-氯-苯基)-乙烯基]-2-甲基-吡啶-3-基}-甲醇2-(3-溴-苯基乙炔基)-6-甲基-吡啶2-甲基-6-(2-[3-(3-三氟甲基-苯氧基)-苯基]-乙烯基}-吡啶2-[2-(3，5-二甲氧基-苯基)-乙烯基]-6-甲基-吡啶2-[2-(3-氯-苯基)-乙烯基]-3-甲氧基-6-甲基-吡啶乙酸4-溴-2-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯基酯乙酸3-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯基酯2-[2-(3，4-二氯-苯基)-乙烯基]-6-甲基-吡啶4-溴-2-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯酚乙酸2-[2-(3，5-二氯-苯基)-乙烯基]-6-甲基-吡啶-3-基酯乙酸6-[2-(3，5-二氯-苯基)-乙烯基]-2-甲基-吡啶-3-基酯乙酸2-[2-(3，5-二氯-苯基)-乙烯基]-吡啶-3-基酯2-甲基-6-(2-萘-1-基-乙烯基)-吡啶2-[2-(3，5-二氢-苯并[1，4]二氧英-6-基)-乙烯基]-6-甲基-吡啶2-甲基-6-(2-萘-2-基-乙烯基)-吡啶2-{2-[3-(3，5-二氯-苯氧基)-苯基]-乙烯基}-6-甲基-吡啶2-[2-(3-氯-苯基)-丙烯基]-6-甲基-吡啶2-[2-(2，3-二氢-苯并呋喃-5-基)-乙烯基]-6-甲基-吡啶2-[2-(4-氟-苯基)-乙烯基]-6-甲基-吡啶2-甲基-6-(2-邻-甲苯基-乙烯基)-吡啶2-甲基-6-(2-对-甲苯基-乙烯基)-吡啶2-甲基-6-(2-对-甲苯基-丙烯基)-吡啶3-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯胺(2，3-二甲氧基-7-硝基-喹喔啉-5-基甲基)-{3-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯基}-胺N-{3-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯基}-乙酰胺N-{3-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯基}-2-苯基-乙酰胺2，2-二甲基-N-{3-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯基}-丙酰胺噻吩-2-甲酸{3-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯基}-酰胺环己烷甲酸{3-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯基}-酰胺1-(4-溴-苯基)-3-{3-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯基}-脲2-甲基-6-[2-(4-硝基-苯基)-乙烯基]-吡啶4-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯胺2-[2-(3，5-二氯-苯基)-乙烯基]-6-甲基-吡啶-3-酚6-[2-(3，5-二氯-苯基)-乙烯基]-2-甲基-吡啶-3-酚2-[2-(3，5-二氯-苯基)-乙烯基]-吡啶-3-酚2-[2-(6-氯-苯并[1，3]二氧戊环-5-基)-乙烯基]-6-甲基-吡啶2-[2-(2，3-二氟-苯基)-乙烯基]-6-甲基-吡啶2-[2-(3，4-二氯-苯基)-丙烯基]-6-甲基-吡啶2-[2-(3，5-二-三氟甲基-苯基)-乙烯基]-6-甲基-吡啶乙酸2-甲氧基-6-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯基酯2-甲氧基-6-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯酚2-甲基-6-[2-(2，3，6-三氟-苯基)-乙烯基]-吡啶2-[2-(4-氟-3-三氟甲基-苯基)-乙烯基]-6-甲基-吡啶2-甲基-6-(2，3，6-三氟-苯基乙炔基)-吡啶乙酸4-氯-2-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯基酯乙酸2，6-二叔丁基-4-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯基酯3-(6-甲基-吡啶-2-基乙炔基)-苯甲酰胺乙酸4-溴-2-甲氧基-6-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯基酯2-(6-氯-苯并[1，3]二氧戊环-5-基乙炔基)-6-甲基-吡啶2-[2-(3，5-二氯-苯基)-乙烯基]-3-甲氧基-6-甲基-吡啶2-[2-(3，5-二氯-苯基)-乙烯基]-3-甲氧基-吡啶5-叠氮基-2-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯酚2-[2-(吡啶-3-基)乙炔基]-6-甲基-吡啶N-{3-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯基}-琥珀酰胺酸1-叔丁基-3-{3-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯基}-脲5-({3-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯基氨基}-甲基)-7-硝基-1，4-二氢-喹喔啉-2，3-二酮四氢-呋喃-2-甲酸{3-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯基}-酰胺(1-{3-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯基氨基甲酰基}-2-苯基-乙基)-氨基甲酸叔丁酯({3-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯基氨基甲酰基}-甲基)-氨基甲酸叔丁酯二乙基-{3-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯基}-胺乙基-{3-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯基}-胺乙基-{3-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯基}-胺2-(2-乙氧基-3，6-二氟-苯基乙炔基)-6-甲基-吡啶2-(3，5-二氟-苯基乙炔基)-6-甲基-吡啶2-(3-氟-苯基乙炔基)-6-甲基-吡啶2-[2-(3，5-二甲基-苯基)-乙烯基]-6-甲基-吡啶2-[2-(3，4-二甲氧基-苯基)-乙烯基]-6-甲基-吡啶2-(3，4-二氯-苯基乙炔基)-6-甲基-吡啶2-(4-乙氧基-3-三氟甲基-苯基乙炔基)-6-甲基-吡啶2-(4-氟-苯基乙炔基)-6-甲基-吡啶2-甲基-6-邻-甲苯基乙炔基-吡啶2-(3，4-二氟-苯基乙炔基)-6-甲基-吡啶2-甲基-6-[2-(2，3，5-三氯-苯基)-乙烯基]-吡啶1-[3-(6-甲基-吡啶-2-基乙炔基)-苯基]-乙酮2-甲基-6-(3-三氟甲基-苯基乙炔基)-吡啶2-甲基-6-(3-硝基-苯基乙炔基)-吡啶6-[2-(3，5-二氯-苯基)-乙烯基]-3-甲氧基-2-甲基-吡啶{2-[2-(2-氯-苯基)-乙烯基]-6-甲基-吡啶-3-基}-吗啉-4-基-甲酮(3-{2-[2-(3，5-二氯-苯基)-乙烯基]-6-甲基-吡啶-3-基氧基}-丙基)-二甲基-胺N-{4-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯基}-琥珀酰胺酸N-{4-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯基}-2-苯基-乙酰胺({4-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯基氨基甲酰基}-甲基)-氨基甲酸叔丁酯1-(叔丁基-3-{4-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯基}-脲{3-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯基}-噻吩-2-基甲基-胺盐酸盐环己基甲基-{3-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯基}-胺盐酸盐{4-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯基}-噻吩-2-基甲基-胺环己基甲基-{4-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯基}-胺2-氨基-N-{3-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯基}-3-苯基-丙酰胺2-氨基-N-{3-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯基}-乙酰胺2-氨基-N-{4-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯基}-乙酰胺1-[1-({2-[2-(2-氯-苯基)-乙烯基]-6-甲基-吡啶-3-基氧基}-乙酰基)-哌啶-4-基]-咪唑烷-2-酮1-{4-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯基氨基}-乙基)-膦酸二甲酯2-(3-乙氧基-4-氟-苯基乙炔基)-6-甲基-吡啶2-(3-氯-苯基乙炔基)-6-甲基-吡啶1-(3-吡啶-2-基乙炔基-苯基)-乙酮4-氯-2-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯酚4-溴-2-甲氧基-6-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯酚2-(2，5-二氟-苯基乙炔基)-6-甲基-吡啶2-(3，5-二甲基-苯基乙炔基)-6-甲基-吡啶2-[2-(3，5-二溴-苯基)-乙烯基]-6-甲基-吡啶3-(6-甲基-吡啶-2-基乙炔基)-苯基氰2-甲基-6-[2-(嘧啶-5-基)-乙炔基]-吡啶(2-{2-[2-(3-氯-苯基)-乙烯基]-6-甲基-吡啶-3-基氧基}-乙基)-二甲基-胺乙酸1-{4-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯基}-乙基酯3-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯酚3-(6-甲基-吡啶-2-基乙炔基)-苯胺N-[3-(6-甲基-吡啶-2-基乙炔基)-苯基]-2-苯基-乙酰胺噻吩-2-甲酸[3-(6-甲基-吡啶-2-基乙炔基)-苯基]-酰胺2-甲基-6-噻吩-2-基乙炔基-吡啶3-(6-甲基-吡啶-2-基乙炔基)-苯甲酸乙酯2-(3，5-二溴-苯基乙炔基)-6-甲基-吡啶{2-[2-(2-氯-苯基)-乙烯基]-6-甲基-吡啶-3-基甲基}-二甲基-胺(3-{6-[2-(3-氯-苯基)-乙烯基]-2-甲基-吡啶-3-基氧基}-丙基)-二甲基-胺5-叠氮基-4-碘-2-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯酚2，6-二-叔丁基-4-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯酚1-{4-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯基}-乙醇2-甲基-6-[2-(嘧啶-2-基)-乙炔基]-吡啶[3-(6-甲基-吡啶-2-基乙炔基)-苯基]-苯基-甲酮6-(6-甲基-吡啶-2-基乙炔基)-3，4-二氢-1H-喹啉-2-酮2-(3-{2-[2-(3-氯-苯基)-乙烯基]-6-甲基-吡啶-3-基氧基}-丙基)-异吲哚-1，3-二酮3-甲氧基-6-甲基-2-间-甲苯基乙炔基-吡啶乙酸2-[2-(6-甲基-吡啶-2-基)-乙烯基]-4-硝基-苯基酯6-(6-甲基-吡啶-2-基乙炔基)-2，3-二氢茚-1-酮2-甲基-6-[2-(吡嗪-2-基)-乙炔基]-吡啶N-甲基-N-(3-{4-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯氧基}-丙基)-乙酰胺2-[2-(3，5-二-三氟甲基-苯基)-1-乙氧基-乙烯基]-6-甲基-吡啶乙酸2-苯基乙炔基-吡啶-3-基酯乙酸6-甲基-2-间-甲苯基乙炔基-吡啶-3-基酯乙酸4-[2-(6-甲基-吡啶-2-基)-乙烯基]-2-硝基-苯基酯2-[2-(6-甲基-吡啶-2-基)-乙烯基]-4-硝基-苯酚二甲基-[3-(2-苯基乙炔基-吡啶-3-基氧基)-丙基]-胺二甲基-(3-{4-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯氧基}-丙基)-胺1-{4-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯基}-乙酮2-(3-氟-苯基乙炔基)-喹啉乙酸2-甲基-6-苯乙烯基-吡啶-3-基酯4-[2-(6-甲基-吡啶-2-基)-乙烯基]-2-硝基-苯酚3-乙氧基-4-[2-(6-甲基-吡啶-2-基)-乙烯基]-2-硝基-苯酚4-(6-甲基-吡啶-2-基乙炔基)-2-硝基-苯酚乙酸2-[2-(6-甲基-吡啶-2-基)-乙烯基]-6-硝基-苯基酯二甲基-[3-(6-甲基-2-苯基乙炔基-吡啶-3-基氧基)-丙基]-胺2-叠氮基-4-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯酚二甲基-[3-(6-甲基-2-间-甲苯基乙炔基-吡啶-3-基氧基)-丙基]-胺2-(3-甲磺酰基-苯基乙炔基)-6-甲基-吡啶3-{2-[2-(3-氯-苯基)-乙烯基]-6-甲基-吡啶-3-基氧基}-丙胺4-叠氮基-N-(3-{2-[2-(3-氯-苯基)-乙烯基]-6-甲基-吡啶-3-基氧基}-丙基)-2-羟基-苯甲酰胺3-[3-(3-二甲氨基-丙氧基)-6-甲基-吡啶-2-基乙炔基]-苯基氰5-(6-甲基-吡啶-2-基乙炔基)-2，3-二氢茚-1-酮2-甲基-6-(2，3，5-三氯-苯基乙炔基)-吡啶2-[2-(6-甲基-吡啶-3-基)乙炔基]-6-甲基-吡啶二甲基-{3-[6-甲基-2-(3-三氟甲基-苯基乙炔基)-吡啶-3-基氧基]-丙基}-胺2-[2-(6-甲基-吡啶-3-基)乙炔基]-3-甲氧基-6-甲基-吡啶盐酸盐2-甲基-6-(5，6，7，8-四氢-萘-2-基乙炔基)-吡啶3-[2-(3-氯-苯基乙炔基)-6-甲基-吡啶-3-基氧基]-丙胺(3-{4-溴-2-甲氧基-6-[2-(6-甲基-吡啶-2-基)-乙烯基]苯氧基}-丙基)-二甲基-胺；[6-(3-氟-苯基乙炔基)-吡啶-2-基]-二甲基-胺6’-(3-氟-苯基乙炔基)-3，4，5，6-四氢-2H-[1，2’]联吡啶{3-[2-(3-氯-苯基乙炔基)-6-甲基-吡啶-3-基氧基]-丙基}-二甲基-胺；4-叠氮基-N-{3-[2-(3-氯-苯基乙炔基)-6-甲基-吡啶-3-基氧基]-丙基}-2-羟基-苯甲酰胺1-[3-(6-甲基-吡啶-2-基乙炔基)-苯基]-1H-[1，2，4]三唑-3-甲酸乙酯1-[3-(6-甲基-2-苯基乙炔基-吡啶-3-基氧基)-丙基]-哌啶-3-醇2-乙炔基-6-(3-氟-苯基乙炔基)-吡啶3-甲基-6-(6-甲基-吡啶-2-基乙炔基)-3H-苯并噁唑-2-酮1-[3-(6-甲基-吡啶-2-基乙炔基)-苯基]-1H-[1，2，4]三唑-3-甲酸1-[3-(6-甲基-吡啶-2-基乙炔基)-苯基]-1H-[1，2，4]三唑-3-甲酸二甲基酰胺1-[3-(6-甲基-2-苯基乙炔基-吡啶-3-基氧基)-丙基]-哌啶-4-醇5-(6-甲基-吡啶-2-基乙炔基)-2-硝基-苯酚5-[2-溴-2-(6-甲基-吡啶-2-基)-乙烯基]-2-硝基-苯酚5-[2-(6-甲基-吡啶-2-基)-反-乙烯基]-2-硝基-苯酚5-[2-(6-甲基-吡啶-2-基)-顺-乙烯基]-2-硝基-苯酚4-叠氮基-2-羟基-N-[3-(6-甲基-吡啶-2-基乙炔基)-苯基]-苯甲酰胺5-(3-二甲氨基-丙氧基)-6-苯基乙炔基-吡啶-2-甲酸乙酯6-甲基-2-苯乙烯基-嘧啶-4-酚2-甲基-6-(3-氟-苯基乙炔基)-吡啶2-(3，5-二氯-苯基乙炔基)-6-甲基-吡啶2-甲基-6-(3-三氟甲氧基-苯基乙炔基)-吡啶2-甲基-6-(3-[1，2，4]三唑-1-基-苯基乙炔基)-吡啶4-(6-甲基-吡啶-2-基乙炔基)-邻苯二甲腈2-甲基-6-{2-[3-(1H-四唑-5-基)-苯基]-乙烯基}-吡啶；具有甲酸的化合物3-[2-(3，5-二氯-苯基乙炔基)-6-甲基-吡啶-3-基氧基]-丙胺{3-[2-(3，5-二氯-苯基乙炔基)-6-甲基-吡啶-3-基氧基]-丙基}-二甲基-胺2-(3，5-二甲基-苯基乙炔基)-3-甲氧基-6-甲基-吡啶2-[2-(3-氟-苯基)-乙烯基]-6-甲基-吡啶-3-酚6-(3-氟-苯基乙炔基)-2-甲基-烟酸乙酯2-叠氮基-5-(6-甲基-吡啶-2-基乙炔基)-苯酚6-(3，4-二甲氧基-苯基乙炔基)-5-(3-二甲氨基-丙氧基)-吡啶-2-甲酸乙酯2-(4-甲氧基-3-三氟甲基-苯基乙炔基)-6-甲基-吡啶2-(3-氟-苯基乙炔基)-6-甲氧基-吡啶2-(3-氟-苯基乙炔基)-5-甲基-吡啶6-(3，5-二氯-苯基乙炔基)-5-(3-二甲氨基-丙氧基)-吡啶-2-甲酸乙酯5-(3-二甲氨基-丙氧基)-6-(3，5-二甲基-苯基乙炔基)-吡啶-2-甲酸乙酯6-(3-氟-苯基乙炔基)-2-甲基-烟酸[6-(3-氟-苯基乙炔基)-2-甲基-吡啶-3-基]-甲醇[4-(4-氟-苯甲酰基)-哌啶-1-基]-[6-(3-氟-苯基乙炔基)-2-甲基-吡啶-3-基]-甲酮2-(3-氟-苯基乙炔基)-6-甲基-烟酸乙酯2-(3-氟-苯基乙炔基)-4，6-二甲基-吡啶6-(3-氟-苯基乙炔基)-N-(5-甲氧基-2，3-二氢茚-2-基甲基)-2-甲基-烟酰胺{[6-(3-氟-苯基乙炔基)-2-甲基-吡啶-3-羰基]-氨基}-苯基-乙酸甲酯2-甲基-6-(5-甲基-噻吩-2-基乙炔基)-吡啶2-甲基-6-(2，3，5-三甲基-苯基乙炔基)-吡啶3-{2-[2-(3-氟-苯基)-乙烯基]-6-甲基-吡啶-3-基氧基}-丙-1-醇[6-(3-氟-苯基乙炔基)-2-甲基-吡啶-3-基甲基]-二甲基-胺2，2-二甲基-丙酸3-[2-(3-氟-苯基乙炔基)-6-甲基-吡啶-3-基氧基]-丙基酯2-叠氮基-4-碘-5-(6-甲基-吡啶-2-基乙炔基)-苯酚6-叠氮基-2，4-二碘-3-(6-甲基-吡啶-2-基乙炔基)-苯酚4-叠氮基-2-羟基-5-碘-N-[3-(6-甲基-吡啶-2-基乙炔基)-苯基]-苯甲酰胺乙酸3-乙酰氧基甲基-5-(6-甲基-吡啶-2-基乙炔基)-苄基酯(苄基-{[2-(3-氟-苯基乙炔基)-6-甲基-吡啶-3-基氧基]-乙酰基}-氨基)-乙酸乙酯2-[2-(3-氟-苯基)-乙烯基]-6-甲基-异烟酸乙酯3-[2-(3-氟-苯基乙炔基)-6-甲基-吡啶-3-基氧基]-丙-1-醇[3-羟甲基-5-(6-甲基-吡啶-2-基乙炔基)-苯基]-甲醇(3-{2-[2-(3，5-二甲基-苯基)-乙烯基]-6-甲基-吡啶-3-基氧基}-丙基)-二甲基-胺[4-(4-氟-苯甲酰基)-哌啶-1-基]-{6-[2-(3-氟-苯基)-乙烯基]-2-甲基-吡啶-3-基}-甲酮2-[2-(3-氟-苯基)-乙烯基]-6-甲基-异烟酸{6-[2-(2-氯-苯基)-乙烯基]-2-甲基-吡啶-3-基}-[4-(4-氟-苯甲酰基)-哌啶-1-基]-甲酮2-(3-乙炔基-苯基乙炔基)-6-甲基-吡啶(3-{2-[2-(2，6-二氯-苯基)-乙烯基]-6-甲基-吡啶-3-基氧基}-丙基)-二甲基-胺(3-{2-[2-(2，3-二氯-苯基)-乙烯基]-6-甲基-吡啶-3-基氧基}-丙基)-二甲基-胺4-[6-(3-氟-苯基乙炔基)-2-甲基-吡啶-3-羰基]-哌嗪-1-甲酸叔丁酯[6-(3-氟-苯基乙炔基)-2-甲基-吡啶-3-基]-哌啶-1-基-甲酮[4-(4-叠氮基-2-羟基-苯甲酰基)-哌嗪-1-基]-[6-(3-氟-苯基乙炔基)-2-甲基-吡啶-3-基]-甲酮(3-{2-[2-(2，4-二氯-苯基)-乙烯基]-6-甲基-吡啶-3-基氧基}-丙基)-二甲基-胺2-(3-氟-苯基乙炔基)-6-甲基-异烟酸乙酯2-(3-氟-苯基乙炔基)-6-甲基-异烟酸叔丁酯2-(3-氟-苯基乙炔基)-6-甲基-异烟酸[2-(3-氟-苯基乙炔基)-6-甲基-吡啶-4-基]-甲醇[4-(4-氟-苯甲酰基)-哌啶-1-基]-[2-(3-氟-苯基乙炔基)-6-甲基-吡啶-4-基]-甲酮3-烯丙氧基-2-[2-(3，5-二氯-苯基)-乙烯基]-6-甲基-吡啶[2-(3-氟-苯基乙炔基)-6-甲基-吡啶-4-基]-吗啉-4-基-甲酮乙酸3-(6-甲基-吡啶-2-基乙炔基)-苄基酯[2-(3-氟-苯基乙炔基)-6-甲基-吡啶-4-基甲基]-二甲基-胺(3-{2-[2-(3，5-二氯-苯基)-丙烯基]-6-甲基-吡啶-3-基氧基}-丙基)-二甲基-胺2-(3-氟-苯基乙炔基)-3-甲氧基-6-甲基-吡啶(3-{2-[2-(3，5-二氯-苯基)-乙烯基]-吡啶-3-基氧基}-丙基)-二甲基-胺(4-叠氮基-2-羟基-5-碘-苯基)-{4-[6-(3-氟-苯基乙炔基)-2-甲基-吡啶-3-羰基]-哌嗪-1-基}-甲酮4-叠氮基-N-{3-[2-(3-氯-苯基乙炔基)-6-甲基-吡啶-3-基氧基]-丙基}-2-羟基-5-碘-苯甲酰胺4-(2-吡啶-2-基-乙烯基)-苯甲酸乙酯(3-{2-[2-(4-氯-苯基)-乙烯基]-6-甲基-吡啶-3-基氧基}-丙基)-二甲基-胺[3-(6-甲基-吡啶-2-基乙炔基)-苯基]-甲醇6-(3-氟-苯基乙炔基)-烟酸叔丁酯(3-{2-[2-(3，4-二氯-苯基)-乙烯基]-6-甲基-吡啶-3-基氧基}-丙基)-二甲基-胺2-(1-溴-2-苯基-乙烯基)-4-甲基-嘧啶6-(3-氟-苯基乙炔基)-烟酸[4-(4-氟-苯甲酰基)-哌啶-1-基]-[6-(3-氟-苯基乙炔基)-吡啶-3-基]-甲酮2-(2-叔丁氧基-3，6-二氟-苯基乙炔基)-6-甲基-吡啶2-甲基-6-[2-(2，4，5-三氟-苯基)-乙烯基]-吡啶2-甲基-6-[2-(2，3，4-三氟-苯基)-乙烯基]-吡啶3-(6-甲基-吡啶-2-基乙炔基)-苯酚2-甲基-6-[2-(3，4，5-三氟-苯基)-乙烯基]-吡啶2-(3-甲氧基-苯基乙炔基)-6-甲基-吡啶2-甲基-6-(2，3，4-三氟-苯基乙炔基)-吡啶及其可药用盐。
10.游离形式或可药用盐形式的(3-{2-[2-反式-(3，5-二氯-苯基)-乙烯基]-6-甲基-吡啶-3-基氧基}-丙基)-二甲基胺。
11.一种药物组合物，包含根据权利要求6-10任一项的游离形式或可药用盐形式的化合物作为药物活性成分及常规药物赋形剂。
12.一种治疗完全或部分由mGluR1或mGluR5介导的疾病的方法，该方法包括用治疗有效量的2-芳基烯基-，2-杂芳基烯基-，2-芳基炔基-，2-杂芳基炔基-，2-芳基偶氮-和2-杂芳基偶氮吡啶或其可药用盐对需要治疗的温血生物体给药。
CNB988070502A 1997-07-11 1998-07-09 吡啶衍生物及其组合物和用途 Expired - Fee Related CN1203060C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US89068997A 1997-07-11 1997-07-11
US89169197A 1997-07-11 1997-07-11
US08/891,691 1997-07-11
US08/890,689 1997-07-11

Publications (2)

Publication Number Publication Date
CN1262676A true CN1262676A (zh) 2000-08-09
CN1203060C CN1203060C (zh) 2005-05-25

Family

ID=27128958

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB988070502A Expired - Fee Related CN1203060C (zh) 1997-07-11 1998-07-09 吡啶衍生物及其组合物和用途

Country Status (26)

Country Link
US (1) US6656957B1 (zh)
EP (1) EP0998459B1 (zh)
JP (1) JP3481208B2 (zh)
KR (1) KR20010021712A (zh)
CN (1) CN1203060C (zh)
AR (1) AR016314A1 (zh)
AT (1) ATE393145T1 (zh)
AU (1) AU738973B2 (zh)
BR (1) BR9811685A (zh)
CA (1) CA2295678C (zh)
DE (1) DE69839398T2 (zh)
ES (1) ES2308811T3 (zh)
HU (1) HUP0004225A3 (zh)
ID (1) ID23889A (zh)
IL (1) IL133904A0 (zh)
MY (1) MY119800A (zh)
NO (1) NO20000124L (zh)
NZ (1) NZ502210A (zh)
PE (1) PE97799A1 (zh)
PL (1) PL343865A1 (zh)
PT (1) PT998459E (zh)
RU (1) RU2203889C2 (zh)
SK (1) SK232000A3 (zh)
TR (1) TR200000059T2 (zh)
TW (1) TW544448B (zh)
WO (1) WO1999002497A2 (zh)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100430059C (zh) * 2001-12-04 2008-11-05 诺瓦提斯公司 具有mGluR5拮抗活性的乙炔衍生物
CN100462363C (zh) * 2003-06-12 2009-02-18 弗·哈夫曼-拉罗切有限公司 作为谷氨酸受体拮抗剂的杂芳基取代的咪唑衍生物
CN101133027B (zh) * 2005-03-04 2011-03-30 弗·哈夫曼-拉罗切有限公司 作为mglur5拮抗剂的吡啶-2-甲酰胺衍生物
CN101001846B (zh) * 2004-06-17 2012-11-07 艾德斯药物股份有限公司 作为促代谢谷氨酸受体的调节剂的炔基衍生物
CN101522624B (zh) * 2006-03-30 2013-11-06 宾夕法尼亚大学理事会 苯乙烯基吡啶衍生物及其用于结合和成像淀粉样蛋白斑的用途
CN107400256A (zh) * 2017-08-14 2017-11-28 毛阿龙 一种抗紫外线塑料添加剂的制备方法

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1187048C (zh) * 1998-10-02 2005-02-02 诺瓦提斯公司 mGLuR拮抗剂用于治疗疼痛和焦虑
WO2000064430A1 (fr) * 1999-04-23 2000-11-02 Sumitomo Pharmaceuticals Co., Ltd. Inhibiteurs de l'apoptose
FR2793245B1 (fr) * 1999-05-05 2002-10-11 Adir Nouveaux composes pyridiniques ou piperidiniques substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6660753B2 (en) 1999-08-19 2003-12-09 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
JP4815083B2 (ja) * 1999-08-31 2011-11-16 メルク・シャープ・エンド・ドーム・コーポレイション 複素環化合物およびそれの使用方法
US6774138B2 (en) 1999-08-31 2004-08-10 Merck & Co., Inc. Thiazolyl(pyridyl)ethyne compounds
GB0005700D0 (en) * 2000-03-09 2000-05-03 Glaxo Group Ltd Therapy
ES2346513T3 (es) * 2000-07-24 2010-10-18 Krenitsky Pharmaceuticals, Inc. 5-alquinil pirimidinas sustituidas que tienen actividad neurotrofica.
WO2002046166A1 (en) 2000-12-04 2002-06-13 F. Hoffmann-La Roche Ag Phenylethenyl or phenylethinyl derivatives as glutamate receptor antagonists
GB0103045D0 (en) * 2001-02-07 2001-03-21 Novartis Ag Organic Compounds
MXPA03007513A (es) * 2001-02-21 2004-07-30 Nps Pharma Inc Compuestos heteropoliciclicos y su uso como antagonistas del receptor metabotropico de glutamato.
US8124625B2 (en) 2001-09-14 2012-02-28 Shionogi & Co., Ltd. Method of enhancing the expression of apolipoprotein AI using olefin derivatives
CA2462442A1 (en) * 2001-10-12 2003-04-24 Warner-Lambert Company Llc Alkyne matrix metalloproteinase inhibitors
US6951875B2 (en) * 2001-10-29 2005-10-04 Hoffmann-La Roche Inc. Conjugated aromatic compounds with a pyridine substituent
WO2003093236A1 (en) * 2002-05-02 2003-11-13 Euro-Celtique, S.A. 1-(pyrid-2-yl)-piperazine compounds as metabotropic glutamate receptor inhibitor
AU2003253149A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc 3,4-dihydroquinolin-2-one, 5,6-fused oxazin-3-one, and 5,6-fused thiazin-3-one derivatives as matrix metalloproteinase inhibitors
AU2003267087A1 (en) * 2002-09-13 2004-04-30 Merck & Co., Inc. Fused heterobicyclo substituted phenyl metabotropic glutamate-5 modulators
WO2004038374A2 (en) * 2002-10-24 2004-05-06 Merck & Co., Inc. Alkyne derivatives as tracers for metabotropic glutamate receptor binding
DE10250708A1 (de) * 2002-10-31 2004-05-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
US7351719B2 (en) 2002-10-31 2008-04-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds
US7452911B2 (en) 2002-10-31 2008-11-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds
ITMI20030151A1 (it) * 2003-01-30 2004-07-31 Recordati Ind Chimica E Farma Ceutica S P A Uso di antagonisti selettivi del recettore mglu5 per il trattamento di disfunzioni neuromuscolari del tratto urinario inferiore.
SI1603877T1 (sl) 2003-03-04 2009-04-30 Addex Pharma Sa Novi derivati aminopiridina kot antagonisti mGiuR5
AU2004218115A1 (en) * 2003-03-07 2004-09-16 Astellas Pharma Inc. Nitrogenous heterocyclic derivative having 2,6-disubstituted styryl
TWI292318B (en) 2003-03-10 2008-01-11 Hoffmann La Roche Imidazol-4-yl-ethynyl-pyridine derivatives
US7531529B2 (en) 2003-06-05 2009-05-12 Roche Palo Alto Llc Imidazole derivatives
UA80888C2 (en) 2003-06-05 2007-11-12 Hoffmann La Roche Imidazole derivatives as glutmate receptor antagonists
PT1641775E (pt) * 2003-07-03 2009-04-23 Euro Celtique Sa Derivados de 2-piridina-alcino úteis para o tratamento da dor
US7091222B2 (en) * 2003-07-03 2006-08-15 Hoffmann-La Roche Inc. Imidazole derivatives
BRPI0415179A (pt) * 2003-10-07 2006-11-28 Renovis Inc derivados de amida como ligandos de canal de ìon e composições farmacêuticas e métodos de empregar as mesmas
WO2005044265A1 (en) * 2003-10-31 2005-05-19 Astrazeneca Ab Alkynes iii
EP1677789A1 (en) * 2003-10-31 2006-07-12 AstraZeneca AB Alkynes i
EP1677790A1 (en) * 2003-10-31 2006-07-12 AstraZeneca AB Alkynes ii
GB0325956D0 (en) * 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
US7592373B2 (en) 2003-12-23 2009-09-22 Boehringer Ingelheim International Gmbh Amide compounds with MCH antagonistic activity and medicaments comprising these compounds
DE102004017934A1 (de) 2004-04-14 2005-11-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
US7524862B2 (en) 2004-04-14 2009-04-28 Boehringer Ingelheim International Gmbh Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds
DE102004017935A1 (de) * 2004-04-14 2005-11-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
DE102004017930A1 (de) * 2004-04-14 2005-11-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
US20050245529A1 (en) * 2004-04-14 2005-11-03 Boehringer Ingelheim International Gmbh Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds
NZ551253A (en) * 2004-06-01 2010-07-30 Hoffmann La Roche Pyridin-4-yl-ethynyl-imidazoles and pyrazoles as MGLU5 receptor antagonists
MXPA06014792A (es) 2004-06-16 2007-02-16 Wyeth Corp Difenilimidazopirimidina y aminas imidazol como inhibidores de ??-secretasa.
ATE444962T1 (de) * 2004-06-16 2009-10-15 Wyeth Corp Amino-5,5-diphenylimidazolon-derivate zur beta- sekretase-hemmung
BRPI0606690A2 (pt) * 2005-01-14 2009-07-14 Wyeth Corp composto; uso do composto para o tratamento de uma doença ou distúrbio associado com uma atividade excessiva de bace; e composição farmacêutica
WO2006074884A1 (en) 2005-01-14 2006-07-20 F.Hoffmann-La Roche Ag Thiazole-4-carboxamide derivatives as mglur5 antagonists
EP1844035A1 (en) * 2005-02-01 2007-10-17 Wyeth Amino-pyridines as inhibitors of beta-secretase
AU2006214627A1 (en) * 2005-02-14 2006-08-24 Wyeth Azolylacylguanidines as beta-secretase inhibitors
US7576099B2 (en) 2005-02-28 2009-08-18 Renovis, Inc. Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
GB0508319D0 (en) * 2005-04-25 2005-06-01 Novartis Ag Organic compounds
AU2006266167A1 (en) * 2005-06-30 2007-01-11 Wyeth Amino-5-(6-membered)heteroarylimidazolone compounds and the use thereof for beta-secretase modulation
TW200738683A (en) * 2005-06-30 2007-10-16 Wyeth Corp Amino-5-(5-membered)heteroarylimidazolone compounds and the use thereof for β-secretase modulation
FR2889188B1 (fr) * 2005-07-28 2007-09-07 Servier Lab Nouveaux composes 1,1-pyridinylaminocyclopropanamines polysubstitues, leur procede de preparation et les compositions phamaceutiques qui les contiennent
FR2889187B1 (fr) * 2005-07-28 2007-09-07 Servier Lab Nouveaux composes 1,1-pyridinyloxycyclopropanamines polysusbstitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
TW200730523A (en) * 2005-07-29 2007-08-16 Wyeth Corp Cycloalkyl amino-hydantoin compounds and use thereof for β-secretase modulation
WO2007035823A2 (en) * 2005-09-20 2007-03-29 Molecular Neuroimaging, Llc Partial mglur5 antagonists and methods of use thereof
CA2623245A1 (en) * 2005-09-26 2007-04-05 Wyeth Amino-5- [4- (difluoromethoxy) phenyl] -5-phenylimidazolone compounds as inhibitors of the beta-secretase (bace)
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
JP2009520027A (ja) * 2005-12-19 2009-05-21 ワイス ２−アミノ−５−ピペリジニルイミダゾロン化合物およびβ−セクレターゼ調節におけるその使用
DE102005062985A1 (de) * 2005-12-28 2007-07-05 Grünenthal GmbH Substituierte bis(hetero)aromatische N-Ethylpropiolamide und ihre Verwendung zur Herstellung von Arzneimitteln
WO2007100536A1 (en) * 2006-02-24 2007-09-07 Wyeth DIHYDROSPIRO[DIBENZO[A,D][7]ANNULENE-5,4'-IMIDAZOL] COMPOUNDS FOR THE INHIBITION OF β-SECRETASE
EA200870514A1 (ru) * 2006-05-08 2009-04-28 Ариад Фармасьютикалз, Инк. Ацетиленовые гетероарильные соединения
US7700606B2 (en) * 2006-08-17 2010-04-20 Wyeth Llc Imidazole amines as inhibitors of β-secretase
CA2662348A1 (en) * 2006-09-21 2008-03-27 Wyeth Indolylalkylpyridin-2-amines for the inhibition of .beta.-secretase
PT2083811T (pt) 2006-11-22 2017-01-23 Clinical Res Ass Llc Métodos de tratamento da síndrome de down, síndrome do x frágil e autismo
NZ577440A (en) * 2006-12-21 2011-12-22 Hoffmann La Roche Polymorphs of a mglur5 receptor antagonist
JP2010519267A (ja) * 2007-02-22 2010-06-03 シンジェンタ パーティシペーションズ アクチェンゲゼルシャフト 新規殺微生物剤
DK2124562T3 (en) 2007-03-09 2016-08-01 Second Genome Inc BICYCLOHETEROARYLFORBINDELSER AS P2X7 modulators and uses thereof
EP2134687A1 (en) * 2007-03-09 2009-12-23 AstraZeneca AB Piperazine and piperidine mglur5 potentiators
PE20090160A1 (es) * 2007-03-20 2009-02-11 Wyeth Corp COMPUESTOS AMINO-5-[4-(DIFLUOROMETOXI)FENIL SUSTITUIDO]-5-FENILIMIDAZOLONA COMO INHIBIDORES DE ß-SECRETASA
AR065814A1 (es) * 2007-03-23 2009-07-01 Wyeth Corp Derivados de 5-fenilimidazolona,inhibidores de beta-secretasa,composiciones farmaceuticas que los contienen y usos para prevenir y/o tratar trastornos asociados a niveles beta-amiloides elevados.
US8853392B2 (en) * 2007-06-03 2014-10-07 Vanderbilt University Benzamide mGluR5 positive allosteric modulators and methods of making and using same
JP5622568B2 (ja) * 2007-06-03 2014-11-12 バンダービルト ユニバーシティ ベンズアミドｍＧｌｕＲ５の正のアロステリック調節因子ならびにその作製および使用方法
GB0713686D0 (en) 2007-07-13 2007-08-22 Addex Pharmaceuticals Sa New compounds 2
US8034806B2 (en) * 2007-11-02 2011-10-11 Vanderbilt University Bicyclic mGluR5 positive allosteric modulators and methods of making and using same
SG171928A1 (en) 2008-12-24 2011-07-28 Astrazeneca Ab Ethanamine compounds and their use for treating depression
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
TWI534144B (zh) * 2009-04-20 2016-05-21 田邊三菱製藥股份有限公司 甲狀腺荷爾蒙β受體作動藥
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
AR080055A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de pirazolo-[5,1-b]-oxazol como antagonistas de los receptores de crf -1
EP2531490B1 (en) 2010-02-02 2014-10-15 Novartis AG Cyclohexyl amide derivatives as crf receptor antagonists
WO2011109398A2 (en) 2010-03-02 2011-09-09 President And Fellows Of Harvard College Methods and compositions for treatment of angelman syndrome and autism spectrum disorders
US8420661B2 (en) * 2010-04-13 2013-04-16 Hoffmann-La Roche Inc. Arylethynyl derivatives
WO2011150380A1 (en) 2010-05-28 2011-12-01 Xenoport, Inc. Methods of treatment of fragile x syndrome, down's syndrome, autism and related disorders
WO2012009646A1 (en) 2010-07-15 2012-01-19 Xenoport, Inc. Methods of treating fragile x syndrome, down's syndrome, autism and related disorders
US8772300B2 (en) * 2011-04-19 2014-07-08 Hoffmann-La Roche Inc. Phenyl or pyridinyl-ethynyl derivatives
US8546416B2 (en) 2011-05-27 2013-10-01 Novartis Ag 3-spirocyclic piperidine derivatives as ghrelin receptor agonists
EP2852591A1 (en) 2012-05-03 2015-04-01 Novartis AG L-malate salt of 2, 7 - diaza - spiro [4.5]dec- 7 - yle derivatives and crystalline forms thereof as ghrelin receptor agonists
MY168937A (en) * 2012-10-18 2019-01-10 Hoffmann La Roche Ethynyl derivatives as modulators of mglur5 receptor activity
MY170152A (en) * 2012-10-18 2019-07-09 Hoffmann La Roche Ethynyl derivative as modulators of mglur5 receptor activity
UA116023C2 (uk) * 2013-07-08 2018-01-25 Ф. Хоффманн-Ля Рош Аг Етинільні похідні як антагоністи метаботропного глутаматного рецептора
EP2853565A1 (en) 2013-09-27 2015-04-01 Consejo Superior De Investigaciones Científicas Glutamate receptor photomodulators
CN106146391A (zh) * 2015-04-15 2016-11-23 中国科学院上海药物研究所 5-芳香炔基取代的苯甲酰胺类化合物及其制备方法、药物组合物和用途
US10995052B2 (en) * 2016-02-03 2021-05-04 Galderma Research & Development Biaromatic propynyl compounds, pharmaceutical and cosmetic compositions containing same, and uses thereof
US10449186B2 (en) * 2017-06-21 2019-10-22 University Of Kentucky Research Foundation Phenylethynyl-substituted benzenes and heterocycles for the treatment of cancer
AU2018310881C1 (en) 2017-07-31 2021-12-16 Novartis Ag Use of mavoglurant in the reduction of cocaine use or in preventing relapse into cocaine use
WO2023122212A2 (en) 2021-12-21 2023-06-29 Southern Research Institute Substituted phenyl ethynyl pyridine carboxamides as potent inhibitors of sars virus

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4006240A (en) * 1975-03-19 1977-02-01 Ho Andrew K S Alcohol aversion process by enzyme inhibition
NO174506B (no) * 1984-10-30 1994-02-07 Usv Pharma Corp Analogifremgangsmaate ved fremstilling av terapeutisk aktive forbindelser
ES2056983T3 (es) * 1988-03-21 1994-10-16 Boehringer Ingelheim Pharma Compuestos para inhibir la biosintesis de metabolitos de acido araquidonico derivados de lipoxigenasa.
US5013744B1 (en) * 1989-12-29 1994-09-20 Allegran Inc Acetylenes disubstituted with a pyridinyl group and a substituted phenyl group having retinoid like activity
WO1992002357A1 (en) * 1990-08-08 1992-02-20 General Electric Company Fabrication of fiber reinforced thermoplastics, with non-woven felt
GB9515412D0 (en) * 1995-07-27 1995-09-27 Pharmacia Spa 2-(4-substituted)-benzylamino-2-methyl-propanamide derivatives
AU6514296A (en) * 1995-07-31 1997-02-26 Novo Nordisk A/S Heterocyclic compounds, their preparation and use
IT1276153B1 (it) * 1995-11-17 1997-10-27 Roberto Pellicciari Derivati di glicina ad attivita' antagonista dei recettori metabotropi del glutammato

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100430059C (zh) * 2001-12-04 2008-11-05 诺瓦提斯公司 具有mGluR5拮抗活性的乙炔衍生物
CN100462363C (zh) * 2003-06-12 2009-02-18 弗·哈夫曼-拉罗切有限公司 作为谷氨酸受体拮抗剂的杂芳基取代的咪唑衍生物
CN101001846B (zh) * 2004-06-17 2012-11-07 艾德斯药物股份有限公司 作为促代谢谷氨酸受体的调节剂的炔基衍生物
CN101133027B (zh) * 2005-03-04 2011-03-30 弗·哈夫曼-拉罗切有限公司 作为mglur5拮抗剂的吡啶-2-甲酰胺衍生物
CN101522624B (zh) * 2006-03-30 2013-11-06 宾夕法尼亚大学理事会 苯乙烯基吡啶衍生物及其用于结合和成像淀粉样蛋白斑的用途
CN107400256A (zh) * 2017-08-14 2017-11-28 毛阿龙 一种抗紫外线塑料添加剂的制备方法

Also Published As

Publication number Publication date
CA2295678C (en) 2010-04-13
CA2295678A1 (en) 1999-01-21
NO20000124L (no) 2000-03-02
ID23889A (id) 2000-05-25
PE97799A1 (es) 1999-11-08
WO1999002497A2 (en) 1999-01-21
DE69839398T2 (de) 2009-05-28
CN1203060C (zh) 2005-05-25
RU2203889C2 (ru) 2003-05-10
TW544448B (en) 2003-08-01
IL133904A0 (en) 2001-04-30
JP2001509504A (ja) 2001-07-24
MY119800A (en) 2005-07-29
ATE393145T1 (de) 2008-05-15
PL343865A1 (en) 2001-09-10
EP0998459A2 (en) 2000-05-10
AU738973B2 (en) 2001-10-04
DE69839398D1 (de) 2008-06-05
HUP0004225A3 (en) 2001-06-28
HUP0004225A2 (hu) 2001-05-28
PT998459E (pt) 2008-07-31
BR9811685A (pt) 2000-09-19
WO1999002497A3 (en) 1999-04-01
JP3481208B2 (ja) 2003-12-22
AU8974398A (en) 1999-02-08
NZ502210A (en) 2002-07-26
SK232000A3 (en) 2000-06-12
TR200000059T2 (tr) 2000-06-21
NO20000124D0 (no) 2000-01-10
ES2308811T3 (es) 2008-12-01
KR20010021712A (ko) 2001-03-15
US6656957B1 (en) 2003-12-02
EP0998459B1 (en) 2008-04-23
AR016314A1 (es) 2001-07-04

Similar Documents

Publication Publication Date Title
CN1203060C (zh) 吡啶衍生物及其组合物和用途
JP5179873B2 (ja) 新規ピリジノン誘導体およびｍＧｌｕＲ２ポジティブアロステリックモジュレーターとしてのその使用
KR100748380B1 (ko) 카나비노이드-1 수용체에서 활성인 치환된 아미드
EP0733033B1 (en) Pharmaceutically active substituted aromatic compounds
JP4719469B2 (ja) 置換アミド類
US4978663A (en) 5-(1-aminocyclohexyl)-2(1H)-pyridinone compounds which have pharmaceutical utility
SK132899A3 (en) NICOTINAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONì (54) COMPRISING THEM
CZ203494A3 (en) Tri-substituted phenyl derivatives, process of their preparation and pharmaceutical preparations in which they are comprised
JP7479725B2 (ja) 化合物、アルデヒドデヒドロゲナーゼ２活性化剤、医薬組成物、並びに治療及び／又は予防薬
JPH08501801A (ja) スチリル誘導体，その調製品とｐｄｅ‐ｉｖ阻害剤としての使用
CA2798360A1 (en) Picolinamide and pyrimidine-4-carboxamide compounds, process for preparing and pharmaceutical composition comprising the same
US6200993B1 (en) Heterosubstituted pyridine derivatives as PDE4 inhibitors
JP4580426B2 (ja) Ｎｋ−１受容体拮抗薬の合成において中間体として使用されるカルボキサミド誘導体の製造方法
CA1339423C (en) Pyridine compounds and pharmaceutical use thereof
US4977165A (en) Piperidine derivative and therapeutic and preventive agents for arrhythmia containing same
CN111741948A (zh) 饱和环稠合的二氢嘧啶酮或二氢三嗪酮化合物及其药物用途
JP2002543064A (ja) Ｐｄｅ４インヒビターとなるヘテロ置換ピリジン誘導体
CN102159544A (zh) γ-分泌酶的吡啶基调节剂
CZ200068A3 (cs) Deriváty pyridinu a farmaceutický prostředek, který je obsahuje
US20090227591A1 (en) Cyclopentene compounds
CA2083956A1 (en) Amide linked pyridyl-benzoic acid derivatives for treating leukotriene-related diseases
US5112981A (en) 5-(1-aminocyclohexyl)-2(1H)-pyridinone and related compounds
US5204480A (en) 5-(1-hydroxylcycloalkyl)-2-methoxy pyridine compounds
KR20050112948A (ko) 1ｈ-피리딘-2-온 유도체
MXPA00000433A (en) Pyridine derivatives

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20050525

Termination date: 20110709